<p>0,The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria.
<p>1,"In order to provide information for the appropriate package insert labeling of progestin-only_oral_contraceptives ( POC ) in the US, a comprehensive review was made of norgestrel (# mg) and norethindrone (# mg), with the clinical differences indicated where applicable."
<p>2,"In order to provide information for the appropriate package insert labeling of progestin-only_oral_contraceptives ( POC ) in the US, a comprehensive review was made of norgestrel (# mg) and norethindrone (# mg), with the clinical differences indicated where applicable."
<p>3,"In order to provide information for the appropriate package insert labeling of progestin-only_oral_contraceptives ( POC ) in the US, a comprehensive review was made of norgestrel (# mg) and norethindrone (# mg), with the clinical differences indicated where applicable."
<p>4,"In order to provide information for the appropriate package insert labeling of progestin-only_oral_contraceptives ( POC ) in the US, a comprehensive review was made of norgestrel (# mg) and norethindrone (# mg), with the clinical differences indicated where applicable."
<p>5,"In order to provide information for the appropriate package insert labeling of progestin-only_oral_contraceptives ( POC ) in the US, a comprehensive review was made of norgestrel (# mg) and norethindrone (# mg), with the clinical differences indicated where applicable."
<p>6,Antimicrobial activity of Ganoderma_lucidum_extract alone and in combination with some antibiotics .
<p>7,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( ampicillin , cefazolin , oxytetracycline and chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain."
<p>8,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( ampicillin , cefazolin , oxytetracycline and chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain."
<p>9,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( ampicillin , cefazolin , oxytetracycline and chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain."
<p>10,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( ampicillin , cefazolin , oxytetracycline and chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain."
<p>11,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( ampicillin , cefazolin , oxytetracycline and chloramphenicol ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain."
<p>12,"The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances."
<p>13,Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
<p>14,"On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts."
<p>15,"However, the absolute number of alcohol -related deaths is far greater than the number of deaths in amphetamine or heroin users."
<p>16,"However, the absolute number of alcohol -related deaths is far greater than the number of deaths in amphetamine or heroin users."
<p>17,"However, the absolute number of alcohol -related deaths is far greater than the number of deaths in amphetamine or heroin users."
<p>18,"Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin , a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin ."
<p>19,"Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin , a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin ."
<p>20,"Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin , a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin ."
<p>21,The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
<p>22,The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
<p>23,The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
<p>24,"Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously."
<p>25,"Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin -induced phosphorylation of this protein in MDA-MB-435 cells."
<p>26,"Diethyl_pyrocarbonate , at pH #, was used to chemically modify exposed histidine residues on toxin_A ."
<p>27,Modification of toxin_A with diethyl_pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel.
<p>28,Treatment of toxin_A with [(14)C]- diethyl_pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules.
<p>29,The effects of diethyl_pyrocarbonate could be reversed by hydroxylamine treatment.
<p>30,"Exposed histidines on toxin_A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin_A using zinc -chelating chromatography."
<p>31,"Exposed histidines on toxin_A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin_A using zinc -chelating chromatography."
<p>32,"Exposed histidines on toxin_A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin_A using zinc -chelating chromatography."
<p>33,"Exposed histidines on toxin_A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin_A using zinc -chelating chromatography."
<p>34,"Note: dissolution of aerosol particles of budesonide in Survanta , a model lung_surfactant ."
<p>35,"Note: dissolution of aerosol particles of budesonide in Survanta , a model lung_surfactant ."
<p>36,"Note: dissolution of aerosol particles of budesonide in Survanta , a model lung_surfactant ."
<p>37,"The effect of a pulmonary_surfactant extract from bovine lung, Survanta , on the dissolution rate of aerosol particles of budesonide was determined."
<p>38,"The effect of a pulmonary_surfactant extract from bovine lung, Survanta , on the dissolution rate of aerosol particles of budesonide was determined."
<p>39,"The effect of a pulmonary_surfactant extract from bovine lung, Survanta , on the dissolution rate of aerosol particles of budesonide was determined."
<p>40,"Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments."
<p>41,"Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies."
<p>42,"Survanta also increased rate of dissolution, in a manner similar to sodium_dodecyl_sulfate ."
<p>43,Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase.
<p>44,Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase.
<p>45,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical_neuroleptic  clozapine ."
<p>46,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical_neuroleptic  clozapine ."
<p>47,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical_neuroleptic  clozapine ."
<p>48,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical_neuroleptic  clozapine ."
<p>49,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical_neuroleptic  clozapine ."
<p>50,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical_neuroleptic  clozapine ."
<p>51,The effects of DCG-IV and L-CCG-1 upon phencyclidine ( PCP )-induced locomotion and behavioral changes in mice.
<p>52,The effects of DCG-IV and L-CCG-1 upon phencyclidine ( PCP )-induced locomotion and behavioral changes in mice.
<p>53,The effects of DCG-IV and L-CCG-1 upon phencyclidine ( PCP )-induced locomotion and behavioral changes in mice.
<p>54,The effects of DCG-IV and L-CCG-1 upon phencyclidine ( PCP )-induced locomotion and behavioral changes in mice.
<p>55,The effects of DCG-IV and L-CCG-1 upon phencyclidine ( PCP )-induced locomotion and behavioral changes in mice.
<p>56,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1 , on the above behavioral changes induced by PCP were found."
<p>57,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1 , on the above behavioral changes induced by PCP were found."
<p>58,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1 , on the above behavioral changes induced by PCP were found."
<p>59,The effects of DCG-IV were very strong and completely depressed the PCP -induced hyperlocomotion.
<p>60,Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital .
<p>61,"Mice from the 20th generation of three lines divergently selected for response to pentobarbital -induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine -induced behavioral sensitization."
<p>62,"18-Methoxycoronaridine ( 18-MC ) and ibogaine : comparison of antiaddictive efficacy, toxicity, and mechanisms of action."
<p>63,"18-Methoxycoronaridine ( 18-MC ) and ibogaine : comparison of antiaddictive efficacy, toxicity, and mechanisms of action."
<p>64,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>65,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>66,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>67,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>68,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>69,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>70,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>71,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>72,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>73,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>74,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>75,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>76,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>77,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>78,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;"
<p>79,"unlike ibogaine , 18-MC does not affect responding for a nondrug reinforcer (water)."
<p>80,Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
<p>81,Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
<p>82,Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
<p>83,"Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens."
<p>84,"Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens."
<p>85,Both ibogaine and 18-MC block morphine -induced and nicotine -induced dopamine release in the nucleus accumbens;
<p>86,Both ibogaine and 18-MC block morphine -induced and nicotine -induced dopamine release in the nucleus accumbens;
<p>87,Both ibogaine and 18-MC block morphine -induced and nicotine -induced dopamine release in the nucleus accumbens;
<p>88,Both ibogaine and 18-MC block morphine -induced and nicotine -induced dopamine release in the nucleus accumbens;
<p>89,Both ibogaine and 18-MC block morphine -induced and nicotine -induced dopamine release in the nucleus accumbens;
<p>90,Both ibogaine and 18-MC block morphine -induced and nicotine -induced dopamine release in the nucleus accumbens;
<p>91,only ibogaine enhances cocaine -induced increases in accumbal dopamine.
<p>92,Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants.
<p>93,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine ;"
<p>94,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine ;"
<p>95,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine ;"
<p>96,"Ibogaine , but not 18-MC , decreases heart rate at high doses."
<p>97,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter."
<p>98,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter."
<p>99,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter."
<p>100,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter."
<p>101,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine , 18-MC probably has an active metabolite."
<p>102,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine , 18-MC probably has an active metabolite."
<p>103,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine , 18-MC probably has an active metabolite."
<p>104,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine , 18-MC probably has an active metabolite."
<p>105,The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine .
<p>106,Clinical implications of warfarin interactions with five sedatives .
<p>107,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>108,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>109,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>110,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>111,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>112,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>113,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>114,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>115,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>116,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>117,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral_hydrate and methaqualone were systematically investigated in # patients receiving coumarin therapy."
<p>118,there was no significant change in prothrombin test results during the trials of chloral_hydrate and methaqualone .
<p>119,Barbiturates and glutethimide should not be administered to patients receiving coumarin_drugs .
<p>120,Barbiturates and glutethimide should not be administered to patients receiving coumarin_drugs .
<p>121,Barbiturates and glutethimide should not be administered to patients receiving coumarin_drugs .
<p>122,"Chloral_hydrate and methaqualone interact pharmacologically with orally administered anticoagulant_agents , but the effect is not clinically significant."
<p>123,"Chloral_hydrate and methaqualone interact pharmacologically with orally administered anticoagulant_agents , but the effect is not clinically significant."
<p>124,"Chloral_hydrate and methaqualone interact pharmacologically with orally administered anticoagulant_agents , but the effect is not clinically significant."
<p>125,It is concluded that chloral_hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
<p>126,It is concluded that chloral_hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
<p>127,It is concluded that chloral_hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
<p>128,Concomitantly given thiazide_diuretics did not interfere with the absorption of a tablet of digoxin .
<p>129,Combinations of clozapine and phencyclidine : effects on drug discrimination and behavioral inhibition in rats.
<p>130,"In the present study, the atypical_antipsychotic  clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures."
<p>131,"In the present study, the atypical_antipsychotic  clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures."
<p>132,"In the present study, the atypical_antipsychotic  clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures."
<p>133,Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone.
<p>134,These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication.
<p>135,"Since chronic dosing is required for therapeutic efficacy of antipsychotics , future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP ."
<p>136,Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
<p>137,Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
<p>138,Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
<p>139,"However, L-NAME (100 and # micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves."
<p>140,Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats.
<p>141,"In noradrenaline -precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium."
<p>142,"If taken # hour before indinavir ( IDV ), didanosine does not affect IDV exposure, despite persistent buffering effects."
<p>143,"If taken # hour before indinavir ( IDV ), didanosine does not affect IDV exposure, despite persistent buffering effects."
<p>144,"If taken # hour before indinavir ( IDV ), didanosine does not affect IDV exposure, despite persistent buffering effects."
<p>145,"If taken # hour before indinavir ( IDV ), didanosine does not affect IDV exposure, despite persistent buffering effects."
<p>146,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir , but it is unclear how soon after didanosine administration indinavir may be given safely."
<p>147,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir , but it is unclear how soon after didanosine administration indinavir may be given safely."
<p>148,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir , but it is unclear how soon after didanosine administration indinavir may be given safely."
<p>149,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir , but it is unclear how soon after didanosine administration indinavir may be given safely."
<p>150,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir , but it is unclear how soon after didanosine administration indinavir may be given safely."
<p>151,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir , but it is unclear how soon after didanosine administration indinavir may be given safely."
<p>152,We compared indinavir pharmacokinetics and gastric pH in # human immunodeficiency virus-positive patients by use of # mg of indinavir alone versus # mg of indinavir administered # h after didanosine administration.
<p>153,We compared indinavir pharmacokinetics and gastric pH in # human immunodeficiency virus-positive patients by use of # mg of indinavir alone versus # mg of indinavir administered # h after didanosine administration.
<p>154,We compared indinavir pharmacokinetics and gastric pH in # human immunodeficiency virus-positive patients by use of # mg of indinavir alone versus # mg of indinavir administered # h after didanosine administration.
<p>155,Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
<p>156,Indinavir may be taken with a light meal # h following the administration of # mg of didanosine .
<p>157,"Cytochalasin_D at # microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within # min."
<p>158,Cytochalasin_D inhibited the carbachol -stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
<p>159,"The percentage of neurons hyperpolarized by mu-selective_opioids , delta(1)-selective_opioids , and kappa-selective_opioids was significantly reduced when 1</p> but not <"
<p>160,Suppression by verapamil of bombesin -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
<p>161,Suppression by verapamil of bombesin -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
<p>162,Suppression by verapamil of bombesin -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
<p>163,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>164,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>165,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>166,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>167,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>168,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>169,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>170,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>171,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>172,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>173,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>174,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>175,"BACKGROUND: The effects of combined administration of bombesin and verapamil_hydrochloride ( verapamil ), a calcium_channel_blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats."
<p>176,"METHODS: From the beginning of the experiment, rats were given # weekly subcutaneous injections of AOM (# mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or # mg/kg body weight) every other day until the end fo the experiment in week 45."
<p>177,"METHODS: From the beginning of the experiment, rats were given # weekly subcutaneous injections of AOM (# mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or # mg/kg body weight) every other day until the end fo the experiment in week 45."
<p>178,"METHODS: From the beginning of the experiment, rats were given # weekly subcutaneous injections of AOM (# mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or # mg/kg body weight) every other day until the end fo the experiment in week 45."
<p>179,"Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis."
<p>180,"Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin ."
<p>181,In vitro interaction of prostaglandin_F2alpha and oxytocin in placental vessels.
<p>182,The interaction of prostaglandin_F2alpha and synthetic oxytocin on placental vessels was studied in vitro.
<p>183,In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha .
<p>184,In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha .
<p>185,In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha .
<p>186,PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin .
<p>187,There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
<p>188,Carbamazepine overdose recognized by a tricyclic_antidepressant assay.
<p>189,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic_antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic_antidepressants .
<p>190,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic_antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic_antidepressants .
<p>191,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic_antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic_antidepressants .
<p>192,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic_antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic_antidepressants .
<p>193,Cypermethrin -induced oxidative stress in rat brain and liver is prevented by vitamin_E or allopurinol .
<p>194,Cypermethrin -induced oxidative stress in rat brain and liver is prevented by vitamin_E or allopurinol .
<p>195,Cypermethrin -induced oxidative stress in rat brain and liver is prevented by vitamin_E or allopurinol .
<p>196,"Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin , a Type_II_pyrethroid ."
<p>197,"Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin_E (100 mg/kg per day, ig, for # days and a dose of # mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within # h."
<p>198,"Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin_E (100 mg/kg per day, ig, for # days and a dose of # mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within # h."
<p>199,"Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin_E (100 mg/kg per day, ig, for # days and a dose of # mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within # h."
<p>200,"Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin_E ."
<p>201,"Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin_E ."
<p>202,"Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin_E ."
<p>203,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>204,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>205,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>206,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>207,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>208,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>209,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective_Ca(2+)_channel_blockers  nimodipine (L-type), omega-conotoxin_GVIA (N-type), or omega-agatoxin_IVA (P-type) in bovine chromaffin cells."
<p>210,Nimodipine had no effect on ginsenosides response.
<p>211,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>212,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>213,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>214,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>215,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>216,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>217,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>218,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>219,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>220,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>221,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin_GVIA -sensitive (N-type) channel, an omega-agatoxin_IVA -sensitive (P-type) channel and nimodipine / omega-conotoxin_GVIA / omega-agatoxin_VIA -resistant (presumptive Q-type) channel."
<p>222,"Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng ."
<p>223,"In vitro activity of KRM-1648 , either singly or in combination with ofloxacin , against Mycobacterium ulcerans."
<p>224,"The antimicrobial effect of a benzoxazinorifamycin , KRM-1648 , either alone or in combination with ofloxacin , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans."
<p>225,"The antimicrobial effect of a benzoxazinorifamycin , KRM-1648 , either alone or in combination with ofloxacin , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans."
<p>226,"The antimicrobial effect of a benzoxazinorifamycin , KRM-1648 , either alone or in combination with ofloxacin , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans."
<p>227,"ulcerans was between # and # mg/l, while corresponding values for rifampicin and rifabutin were in the range of ## mg/l and ## mg/l respectively."
<p>228,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>229,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>230,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>231,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>232,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>233,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>234,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>235,"When combined with ofloxacin , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin ) and ofloxacin ."
<p>236,"The effects of ruthenium_red ( RR ) on inositol_1,4,5-trisphosphate ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry."
<p>237,"The effects of ruthenium_red ( RR ) on inositol_1,4,5-trisphosphate ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry."
<p>238,"The effects of ruthenium_red ( RR ) on inositol_1,4,5-trisphosphate ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry."
<p>239,"The effects of ruthenium_red ( RR ) on inositol_1,4,5-trisphosphate ( InsP(3) )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry."
<p>240,Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
<p>241,Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3) -induced responses.
<p>242,"In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3) -induced responses."
<p>243,"In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3) -mediated responses of megakaryocytes."
<p>244,Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
<p>245,"The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib , at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects."
<p>246,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90</p> confidence interval) for ( rofecoxib + digoxin /placebo + digoxin ) were # (#, #), # (#, #), and # (#, #), respectively."
<p>247,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90</p> confidence interval) for ( rofecoxib + digoxin /placebo + digoxin ) were # (#, #), # (#, #), and # (#, #), respectively."
<p>248,"The harmonic mean elimination half-life was # and # hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively."
<p>249,"The harmonic mean elimination half-life was # and # hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively."
<p>250,"The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was # (+/- #) and # (+/- #) micrograms/120 hours, respectively."
<p>251,Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin .
<p>252,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>253,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>254,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>255,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>256,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>257,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>258,"Concomitant cyclophosphamide , doxorubicin , vincristine , and prednisone chemotherapy plus highly_active_antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma."
<p>259,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>260,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>261,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>262,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>263,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>264,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>265,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>266,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>267,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>268,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>269,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>270,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>271,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>272,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>273,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>274,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>275,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>276,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>277,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>278,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>279,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>280,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>281,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>282,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>283,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>284,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>285,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>286,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>287,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>288,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>289,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>290,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>291,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of # patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of # patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i,e,, cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy."
<p>292,Antiretroviral regimens consisted of two reverse_transcriptase_inhibitors and one protease_inhibitor .
<p>293,Antiretroviral regimens consisted of two reverse_transcriptase_inhibitors and one protease_inhibitor .
<p>294,Antiretroviral regimens consisted of two reverse_transcriptase_inhibitors and one protease_inhibitor .
<p>295,"However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral_drugs and antineoplastic_drugs ."
<p>296,Treatment with antidepressant_drugs can directly interfere with blood glucose levels or may interact with hypoglycemic_agents .
<p>297,Imipramine and clonazepam did not change fasting or overload glycemia.
<p>298,Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
<p>299,Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
<p>300,Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
<p>301,Sertraline neutralized the increase of glycemia induced by oral glucose overload.
<p>302,"Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats."
<p>303,Activity of buforin_II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
<p>304,Activity of buforin_II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
<p>305,Activity of buforin_II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
<p>306,The in vitro anti-cryptosporidial activity of buforin_II alone and in combination with azithromycin and minocycline was investigated.
<p>307,The in vitro anti-cryptosporidial activity of buforin_II alone and in combination with azithromycin and minocycline was investigated.
<p>308,The in vitro anti-cryptosporidial activity of buforin_II alone and in combination with azithromycin and minocycline was investigated.
<p>309,"Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90</p> parasite reduction at the highest concentration tested."
<p>310,Buforin_II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline .
<p>311,Buforin_II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline .
<p>312,Buforin_II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline .
<p>313,Effect of dofetillide on the pharmacokinetics of digoxin .
<p>314,"The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study."
<p>315,Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo;
<p>316,"therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels."
<p>317,"Numerous drug interactions are possible with some anticonvulsant_agents , such as phenobarbitone and phenytoin , which affect hepatic microsomal enzyme systems."
<p>318,"Numerous drug interactions are possible with some anticonvulsant_agents , such as phenobarbitone and phenytoin , which affect hepatic microsomal enzyme systems."
<p>319,"Numerous drug interactions are possible with some anticonvulsant_agents , such as phenobarbitone and phenytoin , which affect hepatic microsomal enzyme systems."
<p>320,Interaction of ketamine and halothane in rats.
<p>321,The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats.
<p>322,"However, halothane anesthetic requirement (i,e,, MAC) was depressed in a dose-dependent fashion as much as 56</p> 1-2 hours and as much as 14% 5-6 hours after injection of ketamine , # mg/kg, im."
<p>323,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
<p>324,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
<p>325,It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
<p>326,Rifampin and warfarin : a drug interaction.
<p>327,The drug interaction between warfarin and rifampin is not well known.
<p>328,Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
<p>329,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
<p>330,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
<p>331,Withdrawal of rifampin decreased the warfarin requirement by 50</p>.
<p>332,"This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin ."
<p>333,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal # to # days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
<p>334,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal # to # days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
<p>335,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal # to # days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
<p>336,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>337,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>338,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>339,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>340,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>341,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>342,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>343,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>344,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>345,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>346,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>347,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>348,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>349,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>350,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>351,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>352,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>353,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>354,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>355,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>356,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>357,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>358,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>359,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>360,"The purpose of this study was to evaluate the effect of sodium_carboxymethylcellulose ( NaCMC ) and carboxymethylcellulose-cysteine ( CMC-Cys ) conjugates on the intestinal permeation of sodium_fluorescein ( NaFlu ) and model peptide drugs, bacitracin and insulin ."
<p>361,Cysteine was covalently linked to carbodiimide activated NaCMC .
<p>362,Unmodified NaCMC (1</p> m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to # and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
<p>363,Unmodified NaCMC (1</p> m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to # and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
<p>364,Unmodified NaCMC (1</p> m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to # and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
<p>365,Unmodified NaCMC (1</p> m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to # and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
<p>366,Unmodified NaCMC (1</p> m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to # and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
<p>367,"Decreasing the concentration of CMC-Cys , exhibiting #</p> (m/m) of immobilised cysteine (CMC-Cys#) from 1% (m/v) to #% (m/v) decreased the R-value of NaFlu from # to #."
<p>368,"Decreasing the concentration of CMC-Cys , exhibiting #</p> (m/m) of immobilised cysteine (CMC-Cys#) from 1% (m/v) to #% (m/v) decreased the R-value of NaFlu from # to #."
<p>369,"Decreasing the concentration of CMC-Cys , exhibiting #</p> (m/m) of immobilised cysteine (CMC-Cys#) from 1% (m/v) to #% (m/v) decreased the R-value of NaFlu from # to #."
<p>370,NaCMC at 1</p> (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
<p>371,NaCMC at 1</p> (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
<p>372,NaCMC at 1</p> (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
<p>373,NaCMC at 1</p> (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
<p>374,NaCMC at 1</p> (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
<p>375,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1</p> m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys # a significantly improved permeation was observed (R= #)."
<p>376,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1</p> m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys # a significantly improved permeation was observed (R= #)."
<p>377,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1</p> m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys # a significantly improved permeation was observed (R= #)."
<p>378,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1</p> m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys # a significantly improved permeation was observed (R= #)."
<p>379,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1</p> m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys # a significantly improved permeation was observed (R= #)."
<p>380,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1</p> m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys # a significantly improved permeation was observed (R= #)."
<p>381,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>382,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>383,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>384,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>385,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>386,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>387,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>388,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>389,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>390,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future."
<p>391,The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
<p>392,The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
<p>393,The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
<p>394,"All subjects received amprenavir (1,200 mg twice a day) for # days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for # days."
<p>395,"All subjects received amprenavir (1,200 mg twice a day) for # days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for # days."
<p>396,"All subjects received amprenavir (1,200 mg twice a day) for # days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for # days."
<p>397,"Cohort # then received amprenavir plus rifabutin for # days, and cohort # received amprenavir plus rifampin for # days."
<p>398,"Cohort # then received amprenavir plus rifabutin for # days, and cohort # received amprenavir plus rifampin for # days."
<p>399,"Cohort # then received amprenavir plus rifabutin for # days, and cohort # received amprenavir plus rifampin for # days."
<p>400,"Cohort # then received amprenavir plus rifabutin for # days, and cohort # received amprenavir plus rifampin for # days."
<p>401,"Cohort # then received amprenavir plus rifabutin for # days, and cohort # received amprenavir plus rifampin for # days."
<p>402,Rifabutin did not significantly affect amprenavir 's pharmacokinetics.
<p>403,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by #-fold and the AUC(ss) of 25-O-desacetylrifabutin by #-fold.
<p>404,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by #-fold and the AUC(ss) of 25-O-desacetylrifabutin by #-fold.
<p>405,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82</p>, but amprenavir had no effect on rifampin pharmacokinetics."
<p>406,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82</p>, but amprenavir had no effect on rifampin pharmacokinetics."
<p>407,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82</p>, but amprenavir had no effect on rifampin pharmacokinetics."
<p>408,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82</p>, but amprenavir had no effect on rifampin pharmacokinetics."
<p>409,"The results of the ERMBT after # weeks of rifabutin and rifampin therapy were increased # and 156</p>, respectively."
<p>410,Amprenavir plus rifampin was well tolerated.
<p>411,"Amprenavir plus rifabutin was poorly tolerated, and # of # subjects discontinued therapy."
<p>412,"Rifampin markedly increases the metabolic clearance of amprenavir , and coadministration is contraindicated."
<p>413,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin , and the combination is poorly tolerated."
<p>414,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin , and the combination is poorly tolerated."
<p>415,"Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT."
<p>416,"Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT."
<p>417,"Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT."
<p>418,"The thiazolidinediones ( rosiglitazone and pioglitazone ), a new class of oral antidiabetic_agents , are ""insulin sensitizers"""
<p>419,"The thiazolidinediones ( rosiglitazone and pioglitazone ), a new class of oral antidiabetic_agents , are ""insulin sensitizers"""
<p>420,"The thiazolidinediones ( rosiglitazone and pioglitazone ), a new class of oral antidiabetic_agents , are ""insulin sensitizers"""
<p>421,"Glucose , alone and in the presence of theophylline , caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals."
<p>422,"Arginine , in the presence of glucose and theophylline , caused excessive glucagon release but nearly normal insulin release in the diabetics."
<p>423,"Arginine , in the presence of glucose and theophylline , caused excessive glucagon release but nearly normal insulin release in the diabetics."
<p>424,"Arginine , in the presence of glucose and theophylline , caused excessive glucagon release but nearly normal insulin release in the diabetics."
<p>425,"Arginine , in the absence of glucose or theophylline , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals."
<p>426,"Arginine , in the absence of glucose or theophylline , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals."
<p>427,"Arginine , in the absence of glucose or theophylline , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals."
<p>428,"Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline , but are relatively insensitive to glucose ."
<p>429,Etofibrate elicited 62</p> enhancement of post- heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
<p>430,"The mode of toxic action of the pesticide gliftor : the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate ."
<p>431,"The mode of toxic action of the pesticide gliftor : the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate ."
<p>432,"The mode of toxic action of the pesticide gliftor : the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate ."
<p>433,"The biochemical toxicology of 1,3-difluoroacetone , a known metabolite of the major ingredient of the pesticide Gliftor ( 1,3-difluoro-2-propanol ), was investigated in vivo and in vitro."
<p>434,"The biochemical toxicology of 1,3-difluoroacetone , a known metabolite of the major ingredient of the pesticide Gliftor ( 1,3-difluoro-2-propanol ), was investigated in vivo and in vitro."
<p>435,"Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro."
<p>436,"Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation."
<p>437,"Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol ."
<p>438,"Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol ."
<p>439,"Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol ."
<p>440,"We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol ."
<p>441,"We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol ."
<p>442,"We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol ."
<p>443,"We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol ."
<p>444,"We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol ."
<p>445,"Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol -intoxicated animals."
<p>446,"Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol -intoxicated animals."
<p>447,"Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol -intoxicated animals."
<p>448,"Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol -intoxicated animals."
<p>449,"Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol -intoxicated animals."
<p>450,"However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats # hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo."
<p>451,"However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats # hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo."
<p>452,"However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats # hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo."
<p>453,"We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway."
<p>454,"We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway."
<p>455,"We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway."
<p>456,"We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway."
<p>457,"We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway."
<p>458,Green_tea_polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
<p>459,"n-dodecyl_gallate showed the most potent inhibition (66</p> inhibition at # microM), which was far more potent than that of crude tannic_acid ."
<p>460,Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
<p>461,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus , a macrolide_immunosuppressant metabolized by CYP3A4, and the calcium_channel_blocker  diltiazem was studied in # healthy subjects."
<p>462,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus , a macrolide_immunosuppressant metabolized by CYP3A4, and the calcium_channel_blocker  diltiazem was studied in # healthy subjects."
<p>463,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus , a macrolide_immunosuppressant metabolized by CYP3A4, and the calcium_channel_blocker  diltiazem was studied in # healthy subjects."
<p>464,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus , a macrolide_immunosuppressant metabolized by CYP3A4, and the calcium_channel_blocker  diltiazem was studied in # healthy subjects."
<p>465,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus , a macrolide_immunosuppressant metabolized by CYP3A4, and the calcium_channel_blocker  diltiazem was studied in # healthy subjects."
<p>466,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus , a macrolide_immunosuppressant metabolized by CYP3A4, and the calcium_channel_blocker  diltiazem was studied in # healthy subjects."
<p>467,Several clinically important interactions have previously been reported for other immunosuppressive_drugs that are metabolized by the same enzyme and for calcium_antagonists .
<p>468,"METHODS: Healthy subjects who were # to # years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus , a single oral 120-mg dose of diltiazem , and the two drugs given together."
<p>469,"RESULTS: The geometric mean (90</p> confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from # to # ng x h/mL, and maximum concentration increased 43% (14%-81%), from # to # ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from # to # hours."
<p>470,"RESULTS: The geometric mean (90</p> confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from # to # ng x h/mL, and maximum concentration increased 43% (14%-81%), from # to # ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from # to # hours."
<p>471,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38</p> and 45%, respectively, when sirolimus was given with diltiazem ."
<p>472,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38</p> and 45%, respectively, when sirolimus was given with diltiazem ."
<p>473,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem , desacetyldiltiazem , and desmethyldiltiazem were unchanged after coadministration of sirolimus , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen."
<p>474,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem , desacetyldiltiazem , and desmethyldiltiazem were unchanged after coadministration of sirolimus , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen."
<p>475,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem , desacetyldiltiazem , and desmethyldiltiazem were unchanged after coadministration of sirolimus , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen."
<p>476,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem , desacetyldiltiazem , and desmethyldiltiazem were unchanged after coadministration of sirolimus , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen."
<p>477,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus ."
<p>478,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus ."
<p>479,"Because of the pronounced intersubject variability in the extent of the sirolimus - diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs."
<p>480,"Because of the pronounced intersubject variability in the extent of the sirolimus - diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs."
<p>481,Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide .
<p>482,OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.
<p>483,OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.
<p>484,"Plasma was analyzed for tolbutamide , and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC."
<p>485,"RESULTS: During treatment with fluvoxamine , there was a statistically significant decrease in the median of the total clearance of tolbutamide , from # mL/h to # mL/h, among the volunteers who received # mg/d."
<p>486,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from # mL/h to # mL/h in the group that received # mg of tolbutamide per day and from # mL/h to # mL/h in the group that received # mg of tolbutamide per day)."
<p>487,"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine ."
<p>488,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin ) when coadministered in de novo kidney allograft recipients during the first year after transplantation."
<p>489,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin ) when coadministered in de novo kidney allograft recipients during the first year after transplantation."
<p>490,"METHOD: This study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of # mg, # mg, or # mg twice daily with cyclosporine and prednisone ."
<p>491,"METHOD: This study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of # mg, # mg, or # mg twice daily with cyclosporine and prednisone ."
<p>492,"METHOD: This study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of # mg, # mg, or # mg twice daily with cyclosporine and prednisone ."
<p>493,"Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12."
<p>494,Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA.
<p>495,"Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = #, #, and #, respectively)."
<p>496,For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.
<p>497,"ADL_8-2698 , a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia."
<p>498,ADL-8-2698 is a novel peripherally_restricted_opioid_antagonist that may selectively prevent opioid -induced gastrointestinal effects without reversing analgesia.
<p>499,ADL-8-2698 is a novel peripherally_restricted_opioid_antagonist that may selectively prevent opioid -induced gastrointestinal effects without reversing analgesia.
<p>500,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in # volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (# mg x kg(-1)), and oral ADL_8-2698 (4 mg) and intravenous morphine (# mg x kg(-1)) in a double blind, cross-over study."
<p>501,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in # volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (# mg x kg(-1)), and oral ADL_8-2698 (4 mg) and intravenous morphine (# mg x kg(-1)) in a double blind, cross-over study."
<p>502,Morphine prolonged gastrointestinal transit time from # to # minutes (P = #); this was prevented by ADL_8-2698 (P = #).
<p>503,Morphine analgesia and pupil constriction were unaffected by ADL_8-2698 and differed from placebo (P < #).
<p>504,We conclude that ADL_8-2698 prevents morphine -induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
<p>505,Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin .
<p>506,OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin .
<p>507,"DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism."
<p>508,The concomitant administration of macrolide_antibiotics and other hydroxymethylglutaryl_coenzyme_A_(HMG-CoA)_reductase_inhibitors have resulted in previous reports of rhabdomyolysis.
<p>509,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>510,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>511,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>512,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>513,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>514,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>515,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>516,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>517,"CONCLUSIONS: Macrolide_antibiotics inhibit the metabolism of HMG-CoA_reductase_inhibitors that are metabolized by CYP3A4 (i,e,, atorvastatin , cerivastatin , lovastatin , simvastatin )."
<p>518,The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine .
<p>519,Quetiapine_fumarate (' Seroquel ') is a newly introduced atypical_antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
<p>520,Quetiapine_fumarate (' Seroquel ') is a newly introduced atypical_antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
<p>521,"This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine , resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder."
<p>522,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>523,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>524,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>525,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>526,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>527,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>528,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>529,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>530,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>531,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>532,"acetaminophen / theophylline , lidocaine / quinidine , phenobarbital / acetaminophen , phenobarbital / valproic_acid , quinidine / lidocaine , theophylline / acetaminophen , and valproic_acid / phenobarbital ."
<p>533,"Similarly dialyzed were phenobarbital , quinidine , and theophylline , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum."
<p>534,"Similarly dialyzed were phenobarbital , quinidine , and theophylline , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum."
<p>535,"Similarly dialyzed were phenobarbital , quinidine , and theophylline , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum."
<p>536,"Acetaminophen diminished the binding of theophylline to human serum by a net change of #</p> (percentage increase in free drug fraction [FDF], #%) at # micromol/L and by a net change of #% (percentage increase in FDF, #%) at # micromol/L."
<p>537,"Theophylline decreased the binding of acetaminophen by a net change of #</p> (percentage increase in FDF, #%) at # micromol/L;"
<p>538,"Valproic_acid diminished binding of phenobarbital by a net change of #</p> (percentage increase in FDF, #%) at # micromol/L."
<p>539,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>540,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>541,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>542,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>543,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>544,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>545,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>546,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>547,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>548,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>549,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>550,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>551,"Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and valproic_acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug."
<p>552,"The serum concentration of phenytoin increased dramatically from # to # microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed."
<p>553,"The serum concentration of phenytoin increased dramatically from # to # microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed."
<p>554,"The serum concentration of phenytoin increased dramatically from # to # microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed."
<p>555,"The serum concentration of phenytoin increased dramatically from # to # microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed."
<p>556,"The serum concentration of phenytoin increased dramatically from # to # microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed."
<p>557,The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine .
<p>558,"Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains."
<p>559,Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
<p>560,AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation.
<p>561,Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
<p>562,Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
<p>563,Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
<p>564,CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation.
<p>565,Lack of interaction between levofloxacin and oxycodone : pharmacokinetics and drug disposition.
<p>566,Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine .
<p>567,Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine .
<p>568,Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine .
<p>569,Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine .
<p>570,Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine .
<p>571,Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine .
<p>572,"This decrease in absorption results in a 36</p> and 50% lower AUC for trovafloxacin and ciprofloxacin , respectively, which could cause clinical failures."
<p>573,The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin .
<p>574,"1 hour after starting the oxycodone or levofloxacin # mg p,o."
<p>575,"There was not a significant difference (p > #) in AUC (# +/- # vs, # +/- #), Cmax (# +/- # vs, # +/- #), and tmax (# +/- # vs, # +/- #) for levofloxacin versus levofloxacin / oxycodone regimens."
<p>576,"It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax."
<p>577,Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
<p>578,Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
<p>579,Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
<p>580,Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine .
<p>581,Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine .
<p>582,Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine .
<p>583,"The zidovudine study dosed subjects with # mg/day of azithromycin (n = 7) (later changed to # mg/day [n = 5]) for Days # to # of a 21-day course of # mg, five times/day of zidovudine ."
<p>584,"The zidovudine study dosed subjects with # mg/day of azithromycin (n = 7) (later changed to # mg/day [n = 5]) for Days # to # of a 21-day course of # mg, five times/day of zidovudine ."
<p>585,Subjects treated with # mg of dideoxyinosine twice daily for # days received # mg of azithromycin or an equivalent amount of placebo/day for Days # to 21.
<p>586,"Azithromycin had no significant impact on the Cmax and AUC of zidovudine , although it significantly decreased the zidovudine tmax by 44</p> and increased the intracellular exposure to phosphorylated zidovudine by 110%."
<p>587,"Azithromycin had no significant impact on the Cmax and AUC of zidovudine , although it significantly decreased the zidovudine tmax by 44</p> and increased the intracellular exposure to phosphorylated zidovudine by 110%."
<p>588,"Azithromycin had no significant impact on the Cmax and AUC of zidovudine , although it significantly decreased the zidovudine tmax by 44</p> and increased the intracellular exposure to phosphorylated zidovudine by 110%."
<p>589,Azithromycin had no significant effect on dideoxyinosine pharmacokinetics.
<p>590,"Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine ."
<p>591,"Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine ."
<p>592,"Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine ."
<p>593,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>594,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>595,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>596,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>597,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>598,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>599,"Effect of diazepam and midazolam on the antinociceptive effect of morphine , metamizol and indomethacin in mice."
<p>600,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>601,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>602,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>603,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>604,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>605,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>606,"The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests."
<p>607,Benzodiazepines were administered to mice # min before applying the analgesic_drugs .
<p>608,Diazepam at doses of # mg/kg and # mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine .
<p>609,Diazepam at doses of # mg/kg and # mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine .
<p>610,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin ."
<p>611,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin ."
<p>612,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin ."
<p>613,"Midazolam used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of morphine , metamizol (only in the tail-flick test) and indomethacin ."
<p>614,"Midazolam used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of morphine , metamizol (only in the tail-flick test) and indomethacin ."
<p>615,"Midazolam used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of morphine , metamizol (only in the tail-flick test) and indomethacin ."
<p>616,Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline .
<p>617,Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline .
<p>618,Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline .
<p>619,"The aim of this study was to investigate the effects of low and high doses of estradiol , and of progesterone on the response to noradrenaline in rat thoracic aorta."
<p>620,"The aim of this study was to investigate the effects of low and high doses of estradiol , and of progesterone on the response to noradrenaline in rat thoracic aorta."
<p>621,"The aim of this study was to investigate the effects of low and high doses of estradiol , and of progesterone on the response to noradrenaline in rat thoracic aorta."
<p>622,"injection of vehicle (corn oil, # mL/day), estradiol (10 microg/kg/day or # mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days."
<p>623,"Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = #+/#, #+/# and #+/#, respectively)."
<p>624,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>625,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>626,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>627,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>628,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>629,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>630,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>631,"Endothelium-intact aortic rings from high- estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone - and progesterone + high- estradiol -treated rats (pD2 values = #+/#, #+/#, #+/# and #+/#, respectively)."
<p>632,"Sildenafil is contraindicated in patients using long-acting_nitrates or who may need to use short-acting_nitrates , because the combination may cause a sharp fall of the blood pressure."
<p>633,"Sildenafil is contraindicated in patients using long-acting_nitrates or who may need to use short-acting_nitrates , because the combination may cause a sharp fall of the blood pressure."
<p>634,"Sildenafil is contraindicated in patients using long-acting_nitrates or who may need to use short-acting_nitrates , because the combination may cause a sharp fall of the blood pressure."
<p>635,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>636,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>637,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>638,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>639,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>640,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>641,"No interactions have been observed with beta-receptor_blockers , calcium_antagonists , thiazide_diuretics and loop_diuretics and ACE_inhibitors ."
<p>642,Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
<p>643,STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men.
<p>644,and phase # (days 45-52): cisapride # mg # times/day (days 45-51) plus fluoxetine # mg/day (days 45-52).
<p>645,Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
<p>646,There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine .
<p>647,Cisapride was well tolerated when administered alone or with fluoxetine .
<p>648,CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine .
<p>649,"Olanzapine , a thienobenzodiazepine_derivative , is a second_generation_(atypical)_antipsychotic_agent which has proven efficacy against the positive and negative symptoms of schizophrenia."
<p>650,"Olanzapine , a thienobenzodiazepine_derivative , is a second_generation_(atypical)_antipsychotic_agent which has proven efficacy against the positive and negative symptoms of schizophrenia."
<p>651,"Olanzapine , a thienobenzodiazepine_derivative , is a second_generation_(atypical)_antipsychotic_agent which has proven efficacy against the positive and negative symptoms of schizophrenia."
<p>652,"In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine # to # mg/day was significantly superior to haloperidol # to # mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms."
<p>653,The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment.
<p>654,"In the first double-blind comparative study (28-week) of olanzapine and risperidone , olanzapine # to # mg/day proved to be significantly more effective than risperidone # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms."
<p>655,"In the first double-blind comparative study (28-week) of olanzapine and risperidone , olanzapine # to # mg/day proved to be significantly more effective than risperidone # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms."
<p>656,"In the first double-blind comparative study (28-week) of olanzapine and risperidone , olanzapine # to # mg/day proved to be significantly more effective than risperidone # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms."
<p>657,"In the first double-blind comparative study (28-week) of olanzapine and risperidone , olanzapine # to # mg/day proved to be significantly more effective than risperidone # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms."
<p>658,"In contrast, preliminary results from an 8-week controlled study suggested risperidone # to # mg/day was superior to olanzapine # to # mg/day against positive and anxiety/depressive symptoms (p < #), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology."
<p>659,"Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol ."
<p>660,"Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol ."
<p>661,"Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol ."
<p>662,"However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder."
<p>663,Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone .
<p>664,Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone .
<p>665,Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone .
<p>666,"In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval."
<p>667,"In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval."
<p>668,"In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval."
<p>669,"In comparison with haloperidol , the adverse events reported significantly more frequently with olanzapine in > or = #</p> of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone , only bodyweight gain occurred significantly more frequently with olanzapine ."
<p>670,"In comparison with haloperidol , the adverse events reported significantly more frequently with olanzapine in > or = #</p> of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone , only bodyweight gain occurred significantly more frequently with olanzapine ."
<p>671,"In comparison with haloperidol , the adverse events reported significantly more frequently with olanzapine in > or = #</p> of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone , only bodyweight gain occurred significantly more frequently with olanzapine ."
<p>672,"In comparison with haloperidol , the adverse events reported significantly more frequently with olanzapine in > or = #</p> of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone , only bodyweight gain occurred significantly more frequently with olanzapine ."
<p>673,"In comparison with haloperidol , the adverse events reported significantly more frequently with olanzapine in > or = #</p> of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone , only bodyweight gain occurred significantly more frequently with olanzapine ."
<p>674,"Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol ."
<p>675,"Compared with risperidone , olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug."
<p>676,"Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol , and to broadly the same extent as risperidone ."
<p>677,"Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol , and to broadly the same extent as risperidone ."
<p>678,"Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol , and to broadly the same extent as risperidone ."
<p>679,"CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia."
<p>680,The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
<p>681,The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
<p>682,The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
<p>683,The emerging roles of non-nucleoside_reverse_transcriptase_inhibitors in antiretroviral therapy.
<p>684,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>685,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>686,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>687,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>688,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>689,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>690,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>691,The availability of potent non-nucleoside_reverse_transcriptase_inhibitor ( NNRTI )-based regimens for antiretroviral therapy and concerns regarding protease_inhibitor ( PI )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
<p>692,"NNRTI -based regimens may have several advantages over PI -based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration."
<p>693,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>694,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>695,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>696,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>697,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>698,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>699,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>700,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>701,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>702,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>703,"Both efavirenz and nevirapine have been compared to triple therapy with the PI  indinavir over # weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz ."
<p>704,A smaller 24-week study has suggested nevirapine may be superior to the PI  nelfinavir .
<p>705,A smaller 24-week study has suggested nevirapine may be superior to the PI  nelfinavir .
<p>706,Limited comparative data in patients with high viral loads treated with nevirapine - or delavirdine -based regimens currently exist.
<p>707,The superiority of efavirenz over indinavir -based regimens has been observed in comparative data in a subset of patients with high viral loads.
<p>708,"Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these # agents may represent the best approach in these circumstances."
<p>709,"METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January # and August # were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil , Viagra , and erectile dysfunction."
<p>710,"METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January # and August # were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil , Viagra , and erectile dysfunction."
<p>711,"RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective_serotonin_reuptake_inhibitors [ SSRIs ])."
<p>712,"RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective_serotonin_reuptake_inhibitors [ SSRIs ])."
<p>713,"however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy."
<p>714,Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
<p>715,"However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans."
<p>716,OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine .
<p>717,"METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to # healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design."
<p>718,"However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine ."
<p>719,"CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans."
<p>720,The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
<p>721,The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
<p>722,The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
<p>723,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>724,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>725,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>726,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>727,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>728,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>729,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>730,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>731,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>732,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>733,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>734,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>735,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>736,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>737,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>738,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>739,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>740,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>741,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>742,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>743,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>744,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>745,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>746,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>747,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>748,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>749,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>750,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>751,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>752,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar_Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital ."
<p>753,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>754,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>755,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>756,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>757,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>758,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>759,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>760,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>761,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>762,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>763,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>764,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar , ketamine , or droperidol but not after administration of fentayl alone or after pentobarbital ."
<p>765,Interaction of clindamycin and gentamicin in vitro.
<p>766,"The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for # aerobic, facultative, and anaerobic clinical isolates."
<p>767,Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (# to # mug/ml);
<p>768,Combinations of clindamycin and gentamicin were indifferent for # strains and synergistic for # strains.
<p>769,"All # strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than # mug/ml) and gentamicin (minimal inhibitory concentration greater than # mug/ml)."
<p>770,Combinations of clindamycin and gentamicin were indifferent for # and synergistic for # of the resistant strains.
<p>771,Molecular basis for the selective toxicity of amphotericin_B for yeast and filipin for animal cells.
<p>772,"Among the polyene_antibiotics , many, like filipin , cannot be used clinically because they are toxic;"
<p>773,Both the toxicity of filipin and the therapeutic value of amphotericin_B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene_antibiotics showed differential effects on cells;
<p>774,Both the toxicity of filipin and the therapeutic value of amphotericin_B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene_antibiotics showed differential effects on cells;
<p>775,Both the toxicity of filipin and the therapeutic value of amphotericin_B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene_antibiotics showed differential effects on cells;
<p>776,"filipin was more potent in lysing human red blood cells, whereas amphotericin_B was more potent in inhibiting yeast cell growth;"
<p>777,"and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin_B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast."
<p>778,"The antifungal_drug , miconazole_nitrate , inhibits the growth of several species of Candida."
<p>779,Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin .
<p>780,"(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body."
<p>781,"(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body."
<p>782,"(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body."
<p>783,"To determine whether probenecid has a direct effect on the distribution of cloxacillin , the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid ."
<p>784,"To determine whether probenecid has a direct effect on the distribution of cloxacillin , the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid ."
<p>785,"To determine whether probenecid has a direct effect on the distribution of cloxacillin , the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid ."
<p>786,"To determine whether probenecid has a direct effect on the distribution of cloxacillin , the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid ."
<p>787,"No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (# and # liters, respectively)."
<p>788,This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
<p>789,"Many people use both alcohol and nicotine (i,e,, cigarettes and other tobacco products)."
<p>790,"The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking."
<p>791,"Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine ."
<p>792,"[Dose-time effects of competitive displacement of radiopertechnetate by sodium_perchlorate following oral and intravenous administration] The effect of various doses of sodium_perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate , in dependence on application mode, was studied."
<p>793,"[Dose-time effects of competitive displacement of radiopertechnetate by sodium_perchlorate following oral and intravenous administration] The effect of various doses of sodium_perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate , in dependence on application mode, was studied."
<p>794,An intravenous dose of # mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous # mg ClO-4- simultaneously or # mg orally # min before the injection of radiopertechnetate .
<p>795,An intravenous dose of # mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous # mg ClO-4- simultaneously or # mg orally # min before the injection of radiopertechnetate .
<p>796,"An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of # min after 99m-TcO-4-injection with a corresponding increase in blood levels."
<p>797,Sirolimus : mammalian target of rapamycin inhibitor to prevent kidney rejection.
<p>798,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>799,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>800,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>801,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>802,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>803,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>804,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>805,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>806,"Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus ."
<p>807,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>808,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>809,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>810,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>811,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>812,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>813,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>814,"While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus , in combination with cyclosporine or tacrolimus , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999)."
<p>815,"The concomitant administration of either cocaine or amphetamine , compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects."
<p>816,"Fluvastatin is the first synthetic_3-hydroxy-3-methylglutaryl_coenzyme_A_(HMGCoA)_reductase_inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986."
<p>817,"Cholestyramine , an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability."
<p>818,"Although this effect was noted even when cholestyramine was given # hours prior to fluvastatin , this regimen did not result in diminished efficacy."
<p>819,"Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin ."
<p>820,"Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin ."
<p>821,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>822,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>823,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>824,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>825,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>826,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>827,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>828,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>829,"Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data."
<p>830,"The literature provides considerable evidence indicating that several, but not all antihistaminics , are indeed analgesic_agents and some are analgesic_adjuvants as well."
<p>831,"The literature provides considerable evidence indicating that several, but not all antihistaminics , are indeed analgesic_agents and some are analgesic_adjuvants as well."
<p>832,"The literature provides considerable evidence indicating that several, but not all antihistaminics , are indeed analgesic_agents and some are analgesic_adjuvants as well."
<p>833,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>834,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>835,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>836,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>837,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>838,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>839,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>840,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>841,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam , phenazepam , phenibut and amizyl and reduces the action of phentolamine ."
<p>842,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>843,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>844,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>845,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>846,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>847,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>848,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>849,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>850,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>851,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>852,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>853,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>854,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>855,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>856,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>857,"[Stimulation by cerulein --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics ] It has been established in experiments on white male rats that prolonged administration (twice a day for # days) of haloperidol (# mg/kg) and pyreneperone (# mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain."
<p>858,"After prolonged administration of neuroleptics the displacing effect of cerulein , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding."
<p>859,"After prolonged administration of neuroleptics the displacing effect of cerulein , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding."
<p>860,"After prolonged administration of neuroleptics the displacing effect of cerulein , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding."
<p>861,It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
<p>862,It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
<p>863,It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
<p>864,Dual effect of ouabain on the palytoxin -induced contraction and norepinephrine release in the guinea-pig vas deferens.
<p>865,"In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;"
<p>866,"When ouabain was applied to the muscle in the presence of phentolamine , both first and second contractile responses to PTX were abolished."
<p>867,"When ouabain was applied to the muscle in the presence of phentolamine , both first and second contractile responses to PTX were abolished."
<p>868,"When ouabain was applied to the muscle in the presence of phentolamine , both first and second contractile responses to PTX were abolished."
<p>869,Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX -induced release.
<p>870,"By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95</p>) from the lumen at As(V) concentrations up to # mM, declining to about 50% absorption at # mM."
<p>871,"Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level."
<p>872,"Vitamin_D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport."
<p>873,"By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone."
<p>874,"Spermine , and to a lesser extent, spermidine , enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction."
<p>875,"Slow-channel_calcium_blockers , such as verapamil , diltiazem and nifedipine , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."
<p>876,"Slow-channel_calcium_blockers , such as verapamil , diltiazem and nifedipine , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."
<p>877,"Slow-channel_calcium_blockers , such as verapamil , diltiazem and nifedipine , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."
<p>878,Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
<p>879,Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
<p>880,Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
<p>881,The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
<p>882,The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
<p>883,The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
<p>884,Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats.
<p>885,"Intrathecal injection of naloxone at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms)."
<p>886,"Intrathecal injection of naloxone at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms)."
<p>887,"Intrathecal injection of naloxone at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms)."
<p>888,"Intrathecal injection of naloxone at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms)."
<p>889,"On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms)."
<p>890,Intraventricular injection of naloxone at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine .
<p>891,Intraventricular injection of naloxone at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine .
<p>892,Intraventricular injection of naloxone at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine .
<p>893,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>894,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>895,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>896,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>897,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>898,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>899,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>900,"The results indicate that a spinal naloxone -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;"
<p>901,"descending epsilon and mu systems for beta-endorphin and morphine , respectively, are proposed."
<p>902,"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine ( MPTP ) and methamphetamine ."
<p>903,"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine ( MPTP ) and methamphetamine ."
<p>904,The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration.
<p>905,It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
<p>906,The MPTP -induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
<p>907,The MPTP -induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
<p>908,The MPTP -induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
<p>909,"Methamphetamine , like MPTP , produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment."
<p>910,"Methamphetamine , like MPTP , produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment."
<p>911,"Methamphetamine , like MPTP , produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment."
<p>912,Dexamethasone and retinyl_acetate similarly inhibit and stimulate EGF - or insulin -induced proliferation of prostatic epithelium.
<p>913,Dexamethasone and retinyl_acetate similarly inhibit and stimulate EGF - or insulin -induced proliferation of prostatic epithelium.
<p>914,Dexamethasone and retinyl_acetate similarly inhibit and stimulate EGF - or insulin -induced proliferation of prostatic epithelium.
<p>915,Dexamethasone and retinyl_acetate similarly inhibit and stimulate EGF - or insulin -induced proliferation of prostatic epithelium.
<p>916,Dexamethasone and retinyl_acetate similarly inhibit and stimulate EGF - or insulin -induced proliferation of prostatic epithelium.
<p>917,Dexamethasone and retinyl_acetate similarly inhibit and stimulate EGF - or insulin -induced proliferation of prostatic epithelium.
<p>918,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>919,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>920,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>921,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>922,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>923,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>924,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>925,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>926,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>927,"Although neither dexamethasone nor retinyl_acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin ."
<p>928,Dexamethasone at 10(-10) M or retinyl_acetate at about # X 10(-9) M inhibits proliferation stimulated by EGF .
<p>929,Dexamethasone at 10(-10) M or retinyl_acetate at about # X 10(-9) M inhibits proliferation stimulated by EGF .
<p>930,Dexamethasone at 10(-10) M or retinyl_acetate at about # X 10(-9) M inhibits proliferation stimulated by EGF .
<p>931,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl_acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF .
<p>932,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl_acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF .
<p>933,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl_acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF .
<p>934,Dexamethasone had a similar effect in the presence of insulin .
<p>935,"However, retinyl_acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin ."
<p>936,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>937,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>938,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>939,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>940,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>941,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>942,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>943,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>944,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>945,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>946,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>947,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>948,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>949,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>950,"These results suggest that both dexamethasone and retinyl_acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF ."
<p>951,"For the calcium-entry_blocking_agents now available in the United States ( verapamil , nifedipine and diltiazem ), these data appeared well after clinical patterns of use evolved."
<p>952,"For the calcium-entry_blocking_agents now available in the United States ( verapamil , nifedipine and diltiazem ), these data appeared well after clinical patterns of use evolved."
<p>953,"For the calcium-entry_blocking_agents now available in the United States ( verapamil , nifedipine and diltiazem ), these data appeared well after clinical patterns of use evolved."
<p>954,"by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine , as well) and the derivative implications for decreased dosing frequency requirements;"
<p>955,"by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine , as well) and the derivative implications for decreased dosing frequency requirements;"
<p>956,Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
<p>957,"The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine"
<p>958,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin , but not in pentazocine and tripelennamine , addicts) were completely inhibited by the drug combination."
<p>959,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin , but not in pentazocine and tripelennamine , addicts) were completely inhibited by the drug combination."
<p>960,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin , but not in pentazocine and tripelennamine , addicts) were completely inhibited by the drug combination."
<p>961,"Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine ."
<p>962,"aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S."
<p>963,Pharmacokinetic evaluation of the digoxin - amiodarone interaction.
<p>964,Amiodarone is known to raise serum digoxin levels.
<p>965,"The pharmacokinetic variables for digoxin were determined after a # mg intravenous dose of digoxin in each subject, before and after oral amiodarone , # mg daily for # weeks."
<p>966,"The pharmacokinetic variables for digoxin were determined after a # mg intravenous dose of digoxin in each subject, before and after oral amiodarone , # mg daily for # weeks."
<p>967,"During amiodarone administration, systemic clearance of digoxin was reduced from # +/- # ml/min (mean +/- standard deviation) to # +/- # ml/min (p less than #)."
<p>968,"Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics."
<p>969,These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
<p>970,These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
<p>971,Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU .
<p>972,"Because the nitrosourea  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU , either alone or in combination with the chemosensitizer misonidazole ."
<p>973,"Because the nitrosourea  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU , either alone or in combination with the chemosensitizer misonidazole ."
<p>974,"Because the nitrosourea  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU , either alone or in combination with the chemosensitizer misonidazole ."
<p>975,"Because the nitrosourea  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU , either alone or in combination with the chemosensitizer misonidazole ."
<p>976,"Because the nitrosourea  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU , either alone or in combination with the chemosensitizer misonidazole ."
<p>977,Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of ##.
<p>978,Misonidazole has a complex effect on oral CCNU pharmacokinetics.
<p>979,We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole .
<p>980,Enhanced theophylline clearance secondary to phenytoin therapy.
<p>981,This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
<p>982,"With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations."
<p>983,The behavioral effects of the stereoisomers of N-allylnormetazocine ( NANM ) were compared with those of phencyclidine ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
<p>984,The behavioral effects of the stereoisomers of N-allylnormetazocine ( NANM ) were compared with those of phencyclidine ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
<p>985,The behavioral effects of the stereoisomers of N-allylnormetazocine ( NANM ) were compared with those of phencyclidine ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
<p>986,The behavioral effects of the stereoisomers of N-allylnormetazocine ( NANM ) were compared with those of phencyclidine ( PCP ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
<p>987,Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
<p>988,"In monkeys, (-)-NANM was about # times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM ."
<p>989,"In monkeys, (-)-NANM was about # times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM ."
<p>990,"In monkeys, (-)-NANM was about # times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM ."
<p>991,"In monkeys, (-)-NANM was about # times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM ."
<p>992,"In both species, (-)-NANM , but not (+)-NANM , antagonized the rate-decreasing effects of morphine on FI and FR responding."
<p>993,"In both species, (-)-NANM , but not (+)-NANM , antagonized the rate-decreasing effects of morphine on FI and FR responding."
<p>994,"In both species, (-)-NANM , but not (+)-NANM , antagonized the rate-decreasing effects of morphine on FI and FR responding."
<p>995,"In monkeys, the effects of (-)-NANM , but not (+)-NANM or PCP , were antagonized by naloxone ;"
<p>996,"In monkeys, the effects of (-)-NANM , but not (+)-NANM or PCP , were antagonized by naloxone ;"
<p>997,"In monkeys, the effects of (-)-NANM , but not (+)-NANM or PCP , were antagonized by naloxone ;"
<p>998,"In monkeys, the effects of (-)-NANM , but not (+)-NANM or PCP , were antagonized by naloxone ;"
<p>999,"In monkeys, the effects of (-)-NANM , but not (+)-NANM or PCP , were antagonized by naloxone ;"
<p>1000,"In monkeys, the effects of (-)-NANM , but not (+)-NANM or PCP , were antagonized by naloxone ;"
<p>1001,the doses of naloxone required to antagonize the effects of (-)-NANM were more than # times higher than those required to antagonize the effects of morphine .
<p>1002,the doses of naloxone required to antagonize the effects of (-)-NANM were more than # times higher than those required to antagonize the effects of morphine .
<p>1003,the doses of naloxone required to antagonize the effects of (-)-NANM were more than # times higher than those required to antagonize the effects of morphine .
<p>1004,"In pigeons, naloxone did not systematically alter the effects of (-)-NANM , (+)-NANM or PCP ."
<p>1005,"In pigeons, naloxone did not systematically alter the effects of (-)-NANM , (+)-NANM or PCP ."
<p>1006,"In pigeons, naloxone did not systematically alter the effects of (-)-NANM , (+)-NANM or PCP ."
<p>1007,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM ."
<p>1008,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM ."
<p>1009,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM ."
<p>1010,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM ."
<p>1011,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM ."
<p>1012,Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
<p>1013,"Since caffeine is frequently co-administered with acetaminophen , it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen ."
<p>1014,"Since caffeine is frequently co-administered with acetaminophen , it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen ."
<p>1015,"Since caffeine is frequently co-administered with acetaminophen , it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen ."
<p>1016,"Since caffeine is frequently co-administered with acetaminophen , it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen ."
<p>1017,Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine .
<p>1018,High-dose cisplatin with sodium_thiosulfate protection.
<p>1019,Sodium_thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
<p>1020,"To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed #-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin ."
<p>1021,"To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed #-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin ."
<p>1022,"To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed #-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin ."
<p>1023,"To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed #-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin ."
<p>1024,Cisplatin was administered over the last two hours of the thiosulfate infusion.
<p>1025,"Comparison of cisplatin pharmacokinetics in patients treated with # mg/m2 plus thiosulfate to those in patients treated with # mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin ."
<p>1026,"Comparison of cisplatin pharmacokinetics in patients treated with # mg/m2 plus thiosulfate to those in patients treated with # mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin ."
<p>1027,"Comparison of cisplatin pharmacokinetics in patients treated with # mg/m2 plus thiosulfate to those in patients treated with # mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin ."
<p>1028,"Comparison of cisplatin pharmacokinetics in patients treated with # mg/m2 plus thiosulfate to those in patients treated with # mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin ."
<p>1029,This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin .
<p>1030,"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin , trichlorfon , and phenobarbital_sodium ."
<p>1031,"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin , trichlorfon , and phenobarbital_sodium ."
<p>1032,"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin , trichlorfon , and phenobarbital_sodium ."
<p>1033,"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin , trichlorfon , and phenobarbital_sodium ."
<p>1034,"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin , trichlorfon , and phenobarbital_sodium ."
<p>1035,"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin , trichlorfon , and phenobarbital_sodium ."
<p>1036,A daily dose of # mg of coumaphos /kg of body weight for # days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers.
<p>1037,"The treatment of ewes with an intravenous (IV) injection of trichlorfon , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with # mg of coumaphos /kg/day."
<p>1038,"In ewes given # mg of phenobarbital_sodium /kg for # days intraperitoneally (IP), the anticholinesterase effect of # mg of coumaphos /kg was significantly reduced and signs of toxicity were not present."
<p>1039,Failure of neomycin to modify ACTH induced hypertension in sheep.
<p>1040,"Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical_steroid dependent hypertension, including ACTH hypertension."
<p>1041,"Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical_steroid dependent hypertension, including ACTH hypertension."
<p>1042,"Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical_steroid dependent hypertension, including ACTH hypertension."
<p>1043,The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep.
<p>1044,Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.
<p>1045,"The present work involved the administration of both ethynyl_estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine."
<p>1046,The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel -treated rats and the levels shown by rats treated with ethynyl_estradiol .
<p>1047,The 20</p> v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol .
<p>1048,These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol .
<p>1049,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol 's influence on components P2 and P3."
<p>1050,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol 's influence on components P2 and P3."
<p>1051,"Atropine , either alone or in combination with alcohol , produced approximately the same degree of enhancement of component P2."
<p>1052,Hypothermia as an index of the disulfiram - ethanol reaction in the rat.
<p>1053,Decreased core temperature in female rats was investigated as one possible index of the disulfiram - ethanol reaction (DER).
<p>1054,Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram # hours before the ethanol challenge.
<p>1055,Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram # hours before the ethanol challenge.
<p>1056,"The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection."
<p>1057,"The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection."
<p>1058,"The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection."
<p>1059,"The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection."
<p>1060,"The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection."
<p>1061,"The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection."
<p>1062,It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
<p>1063,"On the contrary, neurotensin and tuftsin were agonists in induction of analgesia."
<p>1064,It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin .
<p>1065,"Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients."
<p>1066,"Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol ."
<p>1067,Interactions of cobalt and iron in absorption and retention.
<p>1068,"The effects of supplementary oral cobalt and iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of Co and # or # mg/kg of Fe over a period of # days in a total of # rats."
<p>1069,"The effects of supplementary oral cobalt and iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of Co and # or # mg/kg of Fe over a period of # days in a total of # rats."
<p>1070,"The effects of supplementary oral cobalt and iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of Co and # or # mg/kg of Fe over a period of # days in a total of # rats."
<p>1071,"The effects of supplementary oral cobalt and iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of Co and # or # mg/kg of Fe over a period of # days in a total of # rats."
<p>1072,"The effects of supplementary oral cobalt and iron , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of Co and # or # mg/kg of Fe over a period of # days in a total of # rats."
<p>1073,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
<p>1074,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
<p>1075,The lower rate of absorption in the groups receiving # mg Fe instead of # mg of Fe per kg diet resulted in a decreased renal excretion of cobalt .
<p>1076,The lower rate of absorption in the groups receiving # mg Fe instead of # mg of Fe per kg diet resulted in a decreased renal excretion of cobalt .
<p>1077,"Consequently, the effect of iron on the retention of cobalt was lower than on absorption."
<p>1078,"Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred."
<p>1079,"Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred."
<p>1080,"Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred."
<p>1081,"Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred."
<p>1082,"Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe ,(ABSTRACT TRUNCATED AT # WORDS)"
<p>1083,Effect of estradiol on endotoxin -induced changes in steroid hormone levels and lethality in male rats.
<p>1084,We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin .
<p>1085,We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin .
<p>1086,Injection of estradiol # min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin .
<p>1087,Injection of estradiol # min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin .
<p>1088,"The serum estrogen concentrations of estradiol + endotoxin -treated rats decreased by 50</p>, while those of the endotoxin -treated rats increased (2- to 5-fold)."
<p>1089,"The serum estrogen concentrations of estradiol + endotoxin -treated rats decreased by 50</p>, while those of the endotoxin -treated rats increased (2- to 5-fold)."
<p>1090,"The serum androgen concentrations of estradiol + endotoxin -treated rats did not change significantly, while those of endotoxin -treated rats dropped to 30-40</p>"
<p>1091,"The serum androgen concentrations of estradiol + endotoxin -treated rats did not change significantly, while those of endotoxin -treated rats dropped to 30-40</p>"
<p>1092,Exogenous estradiol also appeared to influence the percentage of endotoxin -induced deaths in a dose-dependent manner.
<p>1093,"Loperamide and morphine (# and # mg/kg, s,c."
<p>1094,"Loperamide and morphine (# and # mg/kg, s,c,) inhibited the dmPGE2 (# mg/kg, p,o,)-induced diarrhea in cecectomized rats."
<p>1095,"Loperamide and morphine (# and # mg/kg, s,c,) inhibited the dmPGE2 (# mg/kg, p,o,)-induced diarrhea in cecectomized rats."
<p>1096,"Loperamide and morphine (# and # mg/kg, s,c,) inhibited the dmPGE2 (# mg/kg, p,o,)-induced diarrhea in cecectomized rats."
<p>1097,"N-methyllevallorphan (5 mg/kg, s,c,) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine ."
<p>1098,"N-methyllevallorphan (5 mg/kg, s,c,) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine ."
<p>1099,"N-methyllevallorphan (5 mg/kg, s,c,) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine ."
<p>1100,Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene_diphosphonate (MDP)- gentamicin interaction.
<p>1101,"Gentamicin is an aminoglycoside_antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys."
<p>1102,"Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy."
<p>1103,"Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in # patients."
<p>1104,"Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in # patients."
<p>1105,"Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in # patients."
<p>1106,"This article looks at five commonly used immunosuppressive_drugs in turn ( corticosteroids , cyclosporin , azathioprine , methotrexate , cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise."
<p>1107,"This article looks at five commonly used immunosuppressive_drugs in turn ( corticosteroids , cyclosporin , azathioprine , methotrexate , cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise."
<p>1108,"This article looks at five commonly used immunosuppressive_drugs in turn ( corticosteroids , cyclosporin , azathioprine , methotrexate , cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise."
<p>1109,"This article looks at five commonly used immunosuppressive_drugs in turn ( corticosteroids , cyclosporin , azathioprine , methotrexate , cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise."
<p>1110,"This article looks at five commonly used immunosuppressive_drugs in turn ( corticosteroids , cyclosporin , azathioprine , methotrexate , cyclophosphamide ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise."
<p>1111,"Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde , coexisting in the contents of alcoholic beverages."
<p>1112,These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde ;
<p>1113,Induction of apoptosis in breast cancer cells in response to vitamin_D and antiestrogens .
<p>1114,"1, 25-Dihydroxycholecalciferol_D3 ( 1,25(OH)2D3 ), the active metabolite of vitamin_D , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro."
<p>1115,"1, 25-Dihydroxycholecalciferol_D3 ( 1,25(OH)2D3 ), the active metabolite of vitamin_D , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro."
<p>1116,"In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen  4-hydroxytamoxifen ( TAM ), which also induces apoptosis in MCF-7 cells."
<p>1117,"In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen  4-hydroxytamoxifen ( TAM ), which also induces apoptosis in MCF-7 cells."
<p>1118,"In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen  4-hydroxytamoxifen ( TAM ), which also induces apoptosis in MCF-7 cells."
<p>1119,"In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen  4-hydroxytamoxifen ( TAM ), which also induces apoptosis in MCF-7 cells."
<p>1120,"In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen  4-hydroxytamoxifen ( TAM ), which also induces apoptosis in MCF-7 cells."
<p>1121,"Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone."
<p>1122,"Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation."
<p>1123,These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D -mediated signalling or disruption of estrogen -dependent signalling.
<p>1124,"The anxiogenic effects of theophylline were reduced by pretreatment with CGS_21680 , an A2-selective agonist, but not by N6-cyclopentyladenosine ( CPA ), an A1-selective agonist."
<p>1125,"The anxiogenic effects of theophylline were reduced by pretreatment with CGS_21680 , an A2-selective agonist, but not by N6-cyclopentyladenosine ( CPA ), an A1-selective agonist."
<p>1126,"The anxiogenic effects of theophylline were reduced by pretreatment with CGS_21680 , an A2-selective agonist, but not by N6-cyclopentyladenosine ( CPA ), an A1-selective agonist."
<p>1127,"The anxiogenic effects of theophylline were reduced by pretreatment with CGS_21680 , an A2-selective agonist, but not by N6-cyclopentyladenosine ( CPA ), an A1-selective agonist."
<p>1128,"The anxiogenic effects of theophylline were reduced by pretreatment with CGS_21680 , an A2-selective agonist, but not by N6-cyclopentyladenosine ( CPA ), an A1-selective agonist."
<p>1129,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1130,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1131,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1132,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1133,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1134,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1135,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1136,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1137,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1138,"However, the antagonism of the theophylline -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX -induced anxiogenic effects were neither reversed by CGS_21680 nor by CPA ."
<p>1139,[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant --the drug sandimmune --on hepatic microsomal monooxygenase activities were studied.
<p>1140,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of # mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
<p>1141,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of # mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
<p>1142,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of # mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
<p>1143,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of # mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
<p>1144,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of # mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
<p>1145,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of # mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
<p>1146,The higher verografine and iodamide excretion was due to their increased renal tubular secretion.
<p>1147,"In dogs, cimetidine unchanged the secretion of cardiotrast , a test agent for anionic transport."
<p>1148,Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
<p>1149,Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
<p>1150,Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
<p>1151,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1152,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1153,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1154,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1155,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1156,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1157,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1158,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1159,"Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium_sparing_diuretics , pharmacological doses of vitamin_B6 , physiological doses of vitamin_D and of selenium ."
<p>1160,"Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic_solutions and for preservation of transplants particularly."
<p>1161,Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
<p>1162,"The successive application of glycine (5 or # mg/kg egg weight (e,w,) and glutamate (15 mg/kg e,w,) in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone."
<p>1163,"The successive application of glycine (5 or # mg/kg egg weight (e,w,) and glutamate (15 mg/kg e,w,) in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone."
<p>1164,"The EC50 values for isoproterenol , which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium."
<p>1165,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < #) but not in functional class IV myocardium.
<p>1166,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < #) but not in functional class IV myocardium.
<p>1167,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < #) but not in functional class IV myocardium.
<p>1168,Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30</p> in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < #).
<p>1169,"This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine , in the nonfailing heart only."
<p>1170,Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine .
<p>1171,Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine .
<p>1172,Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine .
<p>1173,[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin_1 and angiotensin_2 on pentagastrin - and histamine -induced gastric acid secretion.
<p>1174,[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin_1 and angiotensin_2 on pentagastrin - and histamine -induced gastric acid secretion.
<p>1175,[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin_1 and angiotensin_2 on pentagastrin - and histamine -induced gastric acid secretion.
<p>1176,[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin_1 and angiotensin_2 on pentagastrin - and histamine -induced gastric acid secretion.
<p>1177,[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin_1 and angiotensin_2 on pentagastrin - and histamine -induced gastric acid secretion.
<p>1178,[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin_1 and angiotensin_2 on pentagastrin - and histamine -induced gastric acid secretion.
<p>1179,It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine .
<p>1180,Interaction of gentamycin and atracurium in anaesthetised horses.
<p>1181,Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40</p> of baseline for # h by atracurium infusion in # horses anaesthetised with halothane .
<p>1182,"Atracurium was again given by infusion to maintain 40</p> twitch for a second hour, then # mg gentamycin /kg bwt were given i,v."
<p>1183,Recovery of hoof twitch from 50</p> to 75% took # +/- # min for atracurium alone and # +/- # min for atracurium plus gentamycin (P = #).
<p>1184,Recovery of hoof twitch from 50</p> to 75% took # +/- # min for atracurium alone and # +/- # min for atracurium plus gentamycin (P = #).
<p>1185,Recovery from 50</p> twitch to 75% fade recovery took # +/- # min for atracurium alone and # +/- # min for atracurium plus gentamycin .
<p>1186,Recovery from 50</p> twitch to 75% fade recovery took # +/- # min for atracurium alone and # +/- # min for atracurium plus gentamycin .
<p>1187,"At 75</p> recovery of fade, hoof twitch was # +/- 3% for atracurium alone and # +/- 4% for atracurium plus gentamycin ."
<p>1188,"At 75</p> recovery of fade, hoof twitch was # +/- 3% for atracurium alone and # +/- 4% for atracurium plus gentamycin ."
<p>1189,"It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium , the effect was minimal."
<p>1190,Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
<p>1191,The benzodiazepines are a family of anxiolytic and hypnotic_drugs .
<p>1192,The benzodiazepines are a family of anxiolytic and hypnotic_drugs .
<p>1193,The benzodiazepines are a family of anxiolytic and hypnotic_drugs .
<p>1194,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine ) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product."
<p>1195,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine ) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product."
<p>1196,"The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis."
<p>1197,Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day # and every # weeks thereafter.
<p>1198,"Population pharmacokinetic analyses revealed that MTX , NSAIDs , corticosteroids , and TNF_blocking_agents did not influence abatacept clearance."
<p>1199,"Population pharmacokinetic analyses revealed that MTX , NSAIDs , corticosteroids , and TNF_blocking_agents did not influence abatacept clearance."
<p>1200,"Population pharmacokinetic analyses revealed that MTX , NSAIDs , corticosteroids , and TNF_blocking_agents did not influence abatacept clearance."
<p>1201,"Population pharmacokinetic analyses revealed that MTX , NSAIDs , corticosteroids , and TNF_blocking_agents did not influence abatacept clearance."
<p>1202,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1203,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1204,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1205,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1206,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1207,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1208,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1209,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1210,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1211,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1212,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF_blocking_agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra ."
<p>1213,Concurrent administration of a TNF_antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF_antagonists alone.
<p>1214,Concurrent administration of a TNF_antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF_antagonists alone.
<p>1215,Concurrent therapy with ORENCIA and TNF_antagonists is not recommended.
<p>1216,"There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra , and therefore such use is not recommended."
<p>1217,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1218,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1219,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1220,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1221,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1222,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1223,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1224,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1225,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1226,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1227,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1228,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1229,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1230,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1231,"These medications have included heparin , warfarin , beta-adrenergic_receptor_blockers , calcium_channel_antagonists , angiotensin_converting_enzyme_inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin ."
<p>1232,Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic_monoclonal_antibodies or therapeutic_monoclonal_antibodies .
<p>1233,The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate .
<p>1234,The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate .
<p>1235,The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate .
<p>1236,The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate .
<p>1237,Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate .
<p>1238,Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate .
<p>1239,Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate .
<p>1240,Co-administration of naltrexone with Acamprosate produced a 25</p> increase in AUC and a 33% increase in the Cmax of acamprosate .
<p>1241,Co-administration of naltrexone with Acamprosate produced a 25</p> increase in AUC and a 33% increase in the Cmax of acamprosate .
<p>1242,The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate .
<p>1243,The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate .
<p>1244,The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate .
<p>1245,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives (including benzodiazepines ), or non-opioid_analgesics was similar to that of subjects taking placebo with these concomitant medications."
<p>1246,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives (including benzodiazepines ), or non-opioid_analgesics was similar to that of subjects taking placebo with these concomitant medications."
<p>1247,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives (including benzodiazepines ), or non-opioid_analgesics was similar to that of subjects taking placebo with these concomitant medications."
<p>1248,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives (including benzodiazepines ), or non-opioid_analgesics was similar to that of subjects taking placebo with these concomitant medications."
<p>1249,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives (including benzodiazepines ), or non-opioid_analgesics was similar to that of subjects taking placebo with these concomitant medications."
<p>1250,"Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone."
<p>1251,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel-blocking_drugs , and isoniazid ."
<p>1252,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel-blocking_drugs , and isoniazid ."
<p>1253,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel-blocking_drugs , and isoniazid ."
<p>1254,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel-blocking_drugs , and isoniazid ."
<p>1255,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel-blocking_drugs , and isoniazid ."
<p>1256,"These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid_products , estrogens , oral contraceptives , phenytoin , nicotinic_acid , sympathomimetics , calcium_channel-blocking_drugs , and isoniazid ."
<p>1257,"When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin , patients should be observed closely for any evidence of hypoglycemia."
<p>1258,"When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin , patients should be observed closely for any evidence of hypoglycemia."
<p>1259,"When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin , patients should be observed closely for any evidence of hypoglycemia."
<p>1260,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1261,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1262,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1263,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1264,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1265,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1266,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1267,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1268,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1269,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1270,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1271,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1272,"Intestinal_adsorbents (e, g,, charcoal ) and digestive_enzyme_preparations containing carbohydrate-splitting enzymes (e, g,, amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly."
<p>1273,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment."
<p>1274,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment."
<p>1275,"Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or ranitidine ."
<p>1276,"Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or ranitidine ."
<p>1277,"Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or ranitidine ."
<p>1278,"Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or ranitidine ."
<p>1279,Acarbose did not interfere with the absorption or disposition of the sulfonylurea  glyburide in diabetic patients.
<p>1280,Acarbose did not interfere with the absorption or disposition of the sulfonylurea  glyburide in diabetic patients.
<p>1281,Acarbose did not interfere with the absorption or disposition of the sulfonylurea  glyburide in diabetic patients.
<p>1282,"Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16</p> (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase)."
<p>1283,"Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16</p> (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase)."
<p>1284,"Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16</p> (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase)."
<p>1285,"Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16</p> (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase)."
<p>1286,"The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values."
<p>1287,"However, the peak plasma level of metformin was reduced by approximately 20</p> when taking Acarbose due to a slight delay in the absorption of metformin ."
<p>1288,"However, the peak plasma level of metformin was reduced by approximately 20</p> when taking Acarbose due to a slight delay in the absorption of metformin ."
<p>1289,There is little if any clinically significant interaction between Acarbose and metformin .
<p>1290,"Catecholamine-depleting_drugs , such as reserpine , may have an additive effect when given with beta-blocking_agents ."
<p>1291,"Catecholamine-depleting_drugs , such as reserpine , may have an additive effect when given with beta-blocking_agents ."
<p>1292,"Catecholamine-depleting_drugs , such as reserpine , may have an additive effect when given with beta-blocking_agents ."
<p>1293,"Patients treated with acebutolol plus catecholamine_depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia."
<p>1294,"Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic_antagonists and alpha-adrenergic_stimulants , including those contained in proprietary cold remedies and vasoconstrictive nasal drops."
<p>1295,Blunting of the antihypertensive effect of beta-adrenoceptor_blocking_agents by nonsteroidal_anti-inflammatory_drugs has been reported.
<p>1296,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin .
<p>1297,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin .
<p>1298,"By decreasing the gastrointestinal absorption of primidone , DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect."
<p>1299,"By decreasing the gastrointestinal absorption of primidone , DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect."
<p>1300,"Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone ."
<p>1301,Acetazolamide may increase the effects of other folic_acid_antagonists .
<p>1302,Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
<p>1303,Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
<p>1304,Acetazolamide may prevent the urinary antiseptic effect of methenamine .
<p>1305,Acetazolamide increases lithium excretion and the lithium may be decreased.
<p>1306,Acetazolamide increases lithium excretion and the lithium may be decreased.
<p>1307,Acetazolamide and sodium_bicarbonate used concurrently increases the risk of renal calculus formation.
<p>1308,Acetazolamide may elevate cyclosporine levels.
<p>1309,Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
<p>1310,Ethanol :Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol .
<p>1311,Ethanol :Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol .
<p>1312,Ethanol :Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol .
<p>1313,Ethanol :Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol .
<p>1314,Ethanol :Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol .
<p>1315,"Glibenclamide : In a study of # healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in # of the # subjects."
<p>1316,"Glibenclamide : In a study of # healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in # of the # subjects."
<p>1317,"Glibenclamide : In a study of # healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in # of the # subjects."
<p>1318,"Glibenclamide : In a study of # healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in # of the # subjects."
<p>1319,"Glibenclamide : In a study of # healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in # of the # subjects."
<p>1320,"Glibenclamide : In a study of # healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide ) in # of the # subjects."
<p>1321,Repeating the study with # healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.
<p>1322,Hormonal_Contraceptives : It has not been established if there is a pharmacokinetic interaction between acitretin and combined_oral_contraceptives .
<p>1323,"However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations."
<p>1324,Microdosed minipill progestin preparations are not recommended for use with Soriatane .
<p>1325,"It is not known whether other progestational_contraceptives , such as implants and injectables, are adequate methods of contraception during acitretin therapy."
<p>1326,Methotrexate : An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate .
<p>1327,"Consequently, the combination of methotrexate with acitretin is also contraindicated."
<p>1328,"Phenytoin : If acitretin is given concurrently with phenytoin , the protein binding of phenytoin may be reduced."
<p>1329,"Phenytoin : If acitretin is given concurrently with phenytoin , the protein binding of phenytoin may be reduced."
<p>1330,"Tetracyclines : Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated."
<p>1331,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1332,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1333,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1334,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1335,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1336,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1337,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1338,Vitamin_A and oral retinoids : Concomitant administration of vitamin_A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
<p>1339,Investigations into the effect of acitretin on the protein binding of anticoagulants_of_the_coumarin_type ( warfarin ) revealed no interaction.
<p>1340,Investigations into the effect of acitretin on the protein binding of anticoagulants_of_the_coumarin_type ( warfarin ) revealed no interaction.
<p>1341,Methotrexate : HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX .
<p>1342,The data do not suggest the need for dose adjustment of either HUMIRA or MTX .
<p>1343,"Anakinra : Concurrent administration of anakinra (an interleukin-1_antagonist ) and another TNF-blocking_agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."
<p>1344,"Anakinra : Concurrent administration of anakinra (an interleukin-1_antagonist ) and another TNF-blocking_agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."
<p>1345,"Anakinra : Concurrent administration of anakinra (an interleukin-1_antagonist ) and another TNF-blocking_agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."
<p>1346,"Anakinra : Concurrent administration of anakinra (an interleukin-1_antagonist ) and another TNF-blocking_agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."
<p>1347,The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.
<p>1348,"Therefore the, combination of anakinra with other TNF-blocking_agents , including HUMIRA , may also result i n similar toxicities."
<p>1349,"Therefore the, combination of anakinra with other TNF-blocking_agents , including HUMIRA , may also result i n similar toxicities."
<p>1350,"Therefore the, combination of anakinra with other TNF-blocking_agents , including HUMIRA , may also result i n similar toxicities."
<p>1351,"Particular caution should be exercised in using preparations containing sulfur , resorcinol , or salicylic_acid in combination with DIFFERIN Gel."
<p>1352,"Particular caution should be exercised in using preparations containing sulfur , resorcinol , or salicylic_acid in combination with DIFFERIN Gel."
<p>1353,"Particular caution should be exercised in using preparations containing sulfur , resorcinol , or salicylic_acid in combination with DIFFERIN Gel."
<p>1354,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e,g,, gentamicin , amikacin ), amphotericin_B , cyclosporine , non-steroidal_anti-inflammatory drugs (e,g,, ibuprofen ), tacrolimus , vancomycin ."
<p>1355,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e,g,, gentamicin , amikacin ), amphotericin_B , cyclosporine , non-steroidal_anti-inflammatory drugs (e,g,, ibuprofen ), tacrolimus , vancomycin ."
<p>1356,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e,g,, gentamicin , amikacin ), amphotericin_B , cyclosporine , non-steroidal_anti-inflammatory drugs (e,g,, ibuprofen ), tacrolimus , vancomycin ."
<p>1357,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e,g,, gentamicin , amikacin ), amphotericin_B , cyclosporine , non-steroidal_anti-inflammatory drugs (e,g,, ibuprofen ), tacrolimus , vancomycin ."
<p>1358,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e,g,, gentamicin , amikacin ), amphotericin_B , cyclosporine , non-steroidal_anti-inflammatory drugs (e,g,, ibuprofen ), tacrolimus , vancomycin ."
<p>1359,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e,g,, gentamicin , amikacin ), amphotericin_B , cyclosporine , non-steroidal_anti-inflammatory drugs (e,g,, ibuprofen ), tacrolimus , vancomycin ."
<p>1360,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1361,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1362,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1363,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1364,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1365,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1366,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1367,"Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine , beta-adrenergic_blocking_agents , calcium_channel_blocking_agents , and angiotensin_converting_enzyme_inhibitors , without any change in the adverse reaction profile."
<p>1368,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard .
<p>1369,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard .
<p>1370,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard .
<p>1371,The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
<p>1372,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
<p>1373,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
<p>1374,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
<p>1375,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
<p>1376,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
<p>1377,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
<p>1378,"In the presence of these methylxanthines , larger doses of adenosine may be required or adenosine may not be effective."
<p>1379,"In the presence of these methylxanthines , larger doses of adenosine may be required or adenosine may not be effective."
<p>1380,Adenosine effects are potentiated by dipyridamole .
<p>1381,"Thus, smaller doses of adenosine may be effective in the presence of dipyridamole ."
<p>1382,"As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine ."
<p>1383,Co-administration with antifungal_agents such as ketoconazole or itraconazole is not recommended.
<p>1384,Co-administration with antifungal_agents such as ketoconazole or itraconazole is not recommended.
<p>1385,Co-administration with antifungal_agents such as ketoconazole or itraconazole is not recommended.
<p>1386,"Nafazodone , fluvoxamine , cimetidine (consider Xanax dose reduction)."
<p>1387,"Nafazodone , fluvoxamine , cimetidine (consider Xanax dose reduction)."
<p>1388,"Nafazodone , fluvoxamine , cimetidine (consider Xanax dose reduction)."
<p>1389,"Nafazodone , fluvoxamine , cimetidine (consider Xanax dose reduction)."
<p>1390,"Nafazodone , fluvoxamine , cimetidine (consider Xanax dose reduction)."
<p>1391,"Nafazodone , fluvoxamine , cimetidine (consider Xanax dose reduction)."
<p>1392,Dexamethasone : Steady-state trough concentrations of albendazole_sulfoxide were about 56</p> higher when # mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
<p>1393,Dexamethasone : Steady-state trough concentrations of albendazole_sulfoxide were about 56</p> higher when # mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
<p>1394,"Praziquantel : In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole_sulfoxide by about 50</p> in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone."
<p>1395,"Praziquantel : In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole_sulfoxide by about 50</p> in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone."
<p>1396,"Praziquantel : In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole_sulfoxide by about 50</p> in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone."
<p>1397,"Praziquantel : In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole_sulfoxide by about 50</p> in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone."
<p>1398,The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).
<p>1399,Cimetidine : Albendazole_sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
<p>1400,Cimetidine : Albendazole_sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
<p>1401,Theophylline : The pharmacokinetics of theophylline ( aminophylline # mg/kg infused over # minutes) were unchanged following a single oral dose of albendazole (400 mg) in # healthy subjects.
<p>1402,Theophylline : The pharmacokinetics of theophylline ( aminophylline # mg/kg infused over # minutes) were unchanged following a single oral dose of albendazole (400 mg) in # healthy subjects.
<p>1403,Theophylline : The pharmacokinetics of theophylline ( aminophylline # mg/kg infused over # minutes) were unchanged following a single oral dose of albendazole (400 mg) in # healthy subjects.
<p>1404,Theophylline : The pharmacokinetics of theophylline ( aminophylline # mg/kg infused over # minutes) were unchanged following a single oral dose of albendazole (400 mg) in # healthy subjects.
<p>1405,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1406,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1407,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1408,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1409,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1410,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1411,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1412,"Concurrent administration of drugs possessing nephrotoxic (e,g,, aminoglycosides , indomethacin ), myelotoxic (e,g,, cytotoxic chemotherapy), cardiotoxic (e,g,, doxorubicin ) or hepatotoxic (e,g,, methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems."
<p>1413,The safety and efficacy of PROLEUKIN in combination with any antineoplastic_agents have not been established.
<p>1414,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1415,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1416,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1417,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1418,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1419,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1420,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1421,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1422,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic_agents , specifically, dacarbazine , cis-platinum , tamoxifen and interferon-alfa ."
<p>1423,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently."
<p>1424,"Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN , including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome."
<p>1425,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1426,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1427,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1428,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1429,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1430,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1431,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1432,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1433,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1434,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1435,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1436,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1437,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1438,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1439,"Although glucocorticoids have been shown to reduce PROLEUKIN -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided, # Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN ."
<p>1440,"Delayed Adverse Reactions to Iodinated_Contrast_Media : A review of the literature revealed that #</p> (range 11-28%) of # patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic_iodinated_contrast_media experienced acute, atypical adverse reactions."
<p>1441,The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.
<p>1442,An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies
<p>1443,Intravenous ranitidine was shown to double the bioavailability of oral alendronate .
<p>1444,Products containing calcium and other multivalent_cations likely will interfere with absorption of alendronate .
<p>1445,Products containing calcium and other multivalent_cations likely will interfere with absorption of alendronate .
<p>1446,Products containing calcium and other multivalent_cations likely will interfere with absorption of alendronate .
<p>1447,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1448,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1449,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1450,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1451,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1452,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1453,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1454,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1455,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1456,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1457,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1458,"Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS_depressants such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics ."
<p>1459,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1460,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1461,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1462,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1463,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1464,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1465,Limited clinical experience indicates that requirements for volatile_inhalation_anesthetics are reduced by # to 50</p> for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
<p>1466,Cimetidine reduces the clearance of ALFENTA .
<p>1467,Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.
<p>1468,"However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers ."
<p>1469,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1470,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1471,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1472,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1473,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1474,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1475,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1476,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1477,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1478,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1479,"Co-administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure."
<p>1480,Co-administration of irbesartan reduced aliskiren Cmax up to 50</p> after multiple dosing.
<p>1481,Co-administration of atorvastatin resulted in about a 50</p> increase in aliskiren Cmax and AUC after multiple dosing.
<p>1482,Ketoconazole : Co-administration of # mg twice-daily ketoconazole with aliskiren resulted in an approximate 80</p> increase in plasma levels of aliskiren .
<p>1483,Ketoconazole : Co-administration of # mg twice-daily ketoconazole with aliskiren resulted in an approximate 80</p> increase in plasma levels of aliskiren .
<p>1484,Ketoconazole : Co-administration of # mg twice-daily ketoconazole with aliskiren resulted in an approximate 80</p> increase in plasma levels of aliskiren .
<p>1485,Ketoconazole : Co-administration of # mg twice-daily ketoconazole with aliskiren resulted in an approximate 80</p> increase in plasma levels of aliskiren .
<p>1486,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1487,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1488,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1489,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1490,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1491,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1492,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1493,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1494,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1495,"Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide ."
<p>1496,Warfarin : The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.
<p>1497,"Furosemide : When aliskiren was co-administered with furosemide , the AUC and Cmax of furosemide were reduced by about 30</p> and 50%, respectively."
<p>1498,"Furosemide : When aliskiren was co-administered with furosemide , the AUC and Cmax of furosemide were reduced by about 30</p> and 50%, respectively."
<p>1499,"Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide ), a common component of insect repellent products."
<p>1500,"Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide ), a common component of insect repellent products."
<p>1501,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1502,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1503,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1504,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1505,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1506,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1507,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1508,"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral_agents , including protease_inhibitors , macrolide_antibiotics , and azole_antifungals , the effect of Panretin gel on the steady-state concentrations of these drugs is not known."
<p>1509,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1510,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1511,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1512,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1513,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1514,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1515,Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric_acid .
<p>1516,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1517,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1518,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1519,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1520,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1521,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1522,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1523,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1524,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1525,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1526,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1527,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1528,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1529,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1530,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1531,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1532,"In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine ."
<p>1533,Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.
<p>1534,"Dicumarol : It has been reported that allopurinol prolongs the half-life of the anticoagulant , dicumarol ."
<p>1535,"Dicumarol : It has been reported that allopurinol prolongs the half-life of the anticoagulant , dicumarol ."
<p>1536,"Dicumarol : It has been reported that allopurinol prolongs the half-life of the anticoagulant , dicumarol ."
<p>1537,The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
<p>1538,"Uricosuric_Agents : Since the excretion of oxipurinol is similar to that of urate, uricosuric_agents , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase."
<p>1539,"Uricosuric_Agents : Since the excretion of oxipurinol is similar to that of urate, uricosuric_agents , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase."
<p>1540,The concomitant administration of uricosuric_agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
<p>1541,The concomitant administration of uricosuric_agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
<p>1542,"Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric_agents , the possibility should be kept in mind."
<p>1543,Thiazide_Diuretics : The reports that the concomitant use of allopurinol and thiazide_diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
<p>1544,Thiazide_Diuretics : The reports that the concomitant use of allopurinol and thiazide_diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
<p>1545,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide_diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected,."
<p>1546,Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
<p>1547,Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
<p>1548,Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
<p>1549,Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
<p>1550,"Cytotoxic_Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic_agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol ."
<p>1551,"Cytotoxic_Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic_agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol ."
<p>1552,"Cytotoxic_Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic_agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol ."
<p>1553,"Cytotoxic_Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic_agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol ."
<p>1554,"Cytotoxic_Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic_agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol ."
<p>1555,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1556,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1557,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1558,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1559,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1560,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1561,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1562,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1563,"However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and/or mechlorethamine ."
<p>1564,"Chlorpropamide : Chlorpropamide s plasma half-life may be prolonged by allopurinol , since allopurinol and chlorpropamide may compete for excretion in the renal tubule."
<p>1565,"Chlorpropamide : Chlorpropamide s plasma half-life may be prolonged by allopurinol , since allopurinol and chlorpropamide may compete for excretion in the renal tubule."
<p>1566,"Chlorpropamide : Chlorpropamide s plasma half-life may be prolonged by allopurinol , since allopurinol and chlorpropamide may compete for excretion in the renal tubule."
<p>1567,"Chlorpropamide : Chlorpropamide s plasma half-life may be prolonged by allopurinol , since allopurinol and chlorpropamide may compete for excretion in the renal tubule."
<p>1568,The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
<p>1569,Cyclosporin : Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol_sodium for injection.
<p>1570,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and AXERT within # hours of each other should be avoided."
<p>1571,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and AXERT within # hours of each other should be avoided."
<p>1572,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and AXERT within # hours of each other should be avoided."
<p>1573,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and AXERT within # hours of each other should be avoided."
<p>1574,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and AXERT within # hours of each other should be avoided."
<p>1575,"Because there is a theoretical basis that these effects may be additive, use of ergotamine -containing or ergot-type_medications (like dihydroergotamine or methysergide ) and AXERT within # hours of each other should be avoided."
<p>1576,Monoamine_Oxidase_Inhibitors : Coadministration of moclobemide resulted in a 27</p> decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
<p>1577,Monoamine_Oxidase_Inhibitors : Coadministration of moclobemide resulted in a 27</p> decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
<p>1578,Monoamine_Oxidase_Inhibitors : Coadministration of moclobemide resulted in a 27</p> decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
<p>1579,Other 5-HT1B/1D_Agonists Concomitant use of other 5-HT1B/1D_agonists within # hours of treatment with AXERT is contraindicated.
<p>1580,Other 5-HT1B/1D_Agonists Concomitant use of other 5-HT1B/1D_agonists within # hours of treatment with AXERT is contraindicated.
<p>1581,Propanolol : The pharmacokinetics of almotriptan were not affected by coadministration of propranolol .
<p>1582,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1583,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1584,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1585,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1586,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1587,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1588,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1589,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1590,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1591,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1592,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1593,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1594,"Selective_Serotonin_Reuptake_Inhibitors ( SSRIs ): SSRIs (e,g,, fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1_agonists ."
<p>1595,"If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised."
<p>1596,Verapamil : Coadministration of almotriptan and verapamil resulted in a 24</p> increase in plasma concentrations of almotriptan .
<p>1597,Verapamil : Coadministration of almotriptan and verapamil resulted in a 24</p> increase in plasma concentrations of almotriptan .
<p>1598,Verapamil : Coadministration of almotriptan and verapamil resulted in a 24</p> increase in plasma concentrations of almotriptan .
<p>1599,Verapamil : Coadministration of almotriptan and verapamil resulted in a 24</p> increase in plasma concentrations of almotriptan .
<p>1600,"Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q,d, for # days) resulted in an approximately 60</p> increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan ."
<p>1601,"Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q,d, for # days) resulted in an approximately 60</p> increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan ."
<p>1602,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1603,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1604,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1605,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1606,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1607,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1608,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1609,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1610,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e,g,, itraconazole , ritonavir , and erythromycin ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications."
<p>1611,"In a pharmacokinetic study, # healthy female subjects received fluvoxamine in escalating doses from # to # mg per day for # days, with coadministration of alosetron # mg on the last day."
<p>1612,Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
<p>1613,Concomitant administration of alosetron and fluvoxamine is contraindicated.
<p>1614,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone_antibiotics and cimetidine , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions."
<p>1615,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone_antibiotics and cimetidine , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions."
<p>1616,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone_antibiotics and cimetidine , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions."
<p>1617,"In a pharmacokinetic study, # healthy female subjects received ketoconazole # mg twice daily for # days, with coadministration of alosetron # mg on the last day."
<p>1618,Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29</p>.
<p>1619,Caution should be used when alosetron and ketoconazole are administered concomitantly.
<p>1620,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease_inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions."
<p>1621,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease_inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions."
<p>1622,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease_inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions."
<p>1623,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease_inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions."
<p>1624,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease_inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions."
<p>1625,"Although not studied with alosetron , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and hydralazine ."
<p>1626,"Although not studied with alosetron , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and hydralazine ."
<p>1627,"Although not studied with alosetron , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and hydralazine ."
<p>1628,Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive_agents  ethinyl_estradiol and levonorgestrel (CYP3A4 substrates).
<p>1629,Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive_agents  ethinyl_estradiol and levonorgestrel (CYP3A4 substrates).
<p>1630,Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive_agents  ethinyl_estradiol and levonorgestrel (CYP3A4 substrates).
<p>1631,Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive_agents  ethinyl_estradiol and levonorgestrel (CYP3A4 substrates).
<p>1632,Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive_agents  ethinyl_estradiol and levonorgestrel (CYP3A4 substrates).
<p>1633,Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive_agents  ethinyl_estradiol and levonorgestrel (CYP3A4 substrates).
<p>1634,A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride .
<p>1635,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1636,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1637,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1638,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1639,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1640,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1641,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1642,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1643,"The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co-administered with other psychotropic_medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression."
<p>1644,"The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31</p> and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to # mg/day."
<p>1645,"The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31</p> and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to # mg/day."
<p>1646,"The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31</p> and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to # mg/day."
<p>1647,"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46</p>, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."
<p>1648,"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46</p>, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."
<p>1649,"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46</p>, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."
<p>1650,"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46</p>, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."
<p>1651,"Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6</p>, decreased clearance by 38%, and increased half-life by 58%."
<p>1652,"Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18</p>, decreased clearance by 22%, and increased half-life by 29%."
<p>1653,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1654,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1655,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1656,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1657,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1658,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1659,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1660,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1661,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1662,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1663,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1664,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1665,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1666,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1667,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1668,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1669,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1670,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1671,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1672,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1673,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1674,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1675,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1676,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1677,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1678,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1679,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1680,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1681,"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem , isoniazid , macrolide_antibiotics such as erythromycin and clarithromycin , and grapefruit juice."
<p>1682,Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine .
<p>1683,Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine .
<p>1684,Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine .
<p>1685,Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine .
<p>1686,Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine .
<p>1687,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1688,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1689,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1690,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1691,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1692,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1693,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1694,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1695,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1696,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1697,"Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine ."
<p>1698,"Standard therapy includes antibiotics , such as penicillin and gentamicin ;"
<p>1699,"Standard therapy includes antibiotics , such as penicillin and gentamicin ;"
<p>1700,"Standard therapy includes antibiotics , such as penicillin and gentamicin ;"
<p>1701,"vasopressors , such as dopamine and isoproterenol ;"
<p>1702,"vasopressors , such as dopamine and isoproterenol ;"
<p>1703,"vasopressors , such as dopamine and isoproterenol ;"
<p>1704,"and diuretics , such as furosemide ."
<p>1705,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1706,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1707,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1708,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1709,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1710,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1711,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1712,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1713,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1714,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1715,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1716,"In addition to bleeding associated with heparin and vitamin_K_antagonists , drugs that alter platelet function (such as acetylsalicylic_acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy."
<p>1717,Use of Antithrombotics  Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
<p>1718,Use of Antithrombotics  Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
<p>1719,Use of Antithrombotics  Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
<p>1720,Use of Antithrombotics  Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
<p>1721,Use of Antithrombotics  Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
<p>1722,Use of Antithrombotics  Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
<p>1723,The concomitant use of heparin or aspirin during the first # hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
<p>1724,"Concurrent administration of HEXALEN and antidepressants_of_the_MAO_inhibitor_class may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model."
<p>1725,"Concurrent administration of HEXALEN and antidepressants_of_the_MAO_inhibitor_class may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model."
<p>1726,"Concurrent administration of HEXALEN and antidepressants_of_the_MAO_inhibitor_class may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model."
<p>1727,"Concurrent administration of HEXALEN and antidepressants_of_the_MAO_inhibitor_class may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model."
<p>1728,"Concurrent administration of HEXALEN and antidepressants_of_the_MAO_inhibitor_class may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model."
<p>1729,"Concurrent administration of HEXALEN and antidepressants_of_the_MAO_inhibitor_class may cause severe orthostatic hypotension, Cimetidine , an inhibitor of microsomal drug metabolism, increased altretamine s half-life and toxicity in a rat model."
<p>1730,Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
<p>1731,Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
<p>1732,Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
<p>1733,Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
<p>1734,Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
<p>1735,"however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin #"
<p>1736,"however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin #"
<p>1737,"however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin #"
<p>1738,Careful observation is required when amantadine is administered concurrently with central_nervous_system_stimulants .
<p>1739,Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive_medications or other drugs that could cause or potentiate hypotension.
<p>1740,"When amiloride HCl is administered concomitantly with an angiotensin-converting_enzyme_inhibitor , the risk of hyperkalemia may be increased."
<p>1741,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
<p>1742,"In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."
<p>1743,"In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."
<p>1744,"In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."
<p>1745,"In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."
<p>1746,"In some patients, the administration of a non-steroidal_anti-inflammatory_agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop_diuretics , potassium-sparing_diuretics and thiazide_diuretics ."
<p>1747,"Therefore, when MIDAMOR and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."
<p>1748,"Therefore, when MIDAMOR and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."
<p>1749,"Therefore, when MIDAMOR and non-steroidal_anti-inflammatory_agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."
<p>1750,"Since indomethacin and potassium-sparing_diuretics , including MIDAMOR , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."
<p>1751,"Since indomethacin and potassium-sparing_diuretics , including MIDAMOR , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."
<p>1752,"Since indomethacin and potassium-sparing_diuretics , including MIDAMOR , may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."
<p>1753,Cytadren accelerates the metabolism of dexamethasone ;
<p>1754,"therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed."
<p>1755,Aminoglutethimide diminishes the effect of coumarin and warfarin .
<p>1756,Aminoglutethimide diminishes the effect of coumarin and warfarin .
<p>1757,Aminoglutethimide diminishes the effect of coumarin and warfarin .
<p>1758,"Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or thiazolesulfone ."
<p>1759,"Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or thiazolesulfone ."
<p>1760,"Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or thiazolesulfone ."
<p>1761,Probenecid depresses tubular secretion of certain weak acids such as PAH .
<p>1762,"Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values."
<p>1763,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1764,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1765,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1766,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1767,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1768,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1769,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1770,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1771,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1772,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1773,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1774,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1775,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1776,"It is, however, possible that concomitant use of other known photosensitizing_agents such as griseofulvin , thiazide_diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN_KERASTICK for Topical Solution."
<p>1777,"Aminosalicylic_acid may decrease the amount of digoxin ( Lanoxin , Lanoxicaps ) that gets absorbed into your body."
<p>1778,"Aminosalicylic_acid may decrease the amount of digoxin ( Lanoxin , Lanoxicaps ) that gets absorbed into your body."
<p>1779,"Aminosalicylic_acid may decrease the amount of digoxin ( Lanoxin , Lanoxicaps ) that gets absorbed into your body."
<p>1780,"In the case that you are taking digoxin while taking aminosalicylic_acid , higher doses of digoxin may be needed."
<p>1781,"In the case that you are taking digoxin while taking aminosalicylic_acid , higher doses of digoxin may be needed."
<p>1782,"Aminosalicylic_acid may also decrease the absorption of vitamin_B12 , which can lead to a deficiency."
<p>1783,Therefore you may need to take a vitamin_B12 supplement while taking aminosalicylic_acid .
<p>1784,A case report of one patient taking amiodarone # mg and indinavir # mg three times a day resulted in increases in amiodarone concentrations from # mg/L to # mg/L.
<p>1785,A case report of one patient taking amiodarone # mg and indinavir # mg three times a day resulted in increases in amiodarone concentrations from # mg/L to # mg/L.
<p>1786,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease_inhibitor therapy should be considered.
<p>1787,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease_inhibitor therapy should be considered.
<p>1788,Histamine_H2_antagonists : Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
<p>1789,"Amiodarone may suppress certain CYP450 enzymes, including CYP1A2 , CYP2C9 , CYP2D6 , and CYP3A4 ."
<p>1790,"Amiodarone may suppress certain CYP450 enzymes, including CYP1A2 , CYP2C9 , CYP2D6 , and CYP3A4 ."
<p>1791,"Amiodarone may suppress certain CYP450 enzymes, including CYP1A2 , CYP2C9 , CYP2D6 , and CYP3A4 ."
<p>1792,"Amiodarone may suppress certain CYP450 enzymes, including CYP1A2 , CYP2C9 , CYP2D6 , and CYP3A4 ."
<p>1793,"Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine ."
<p>1794,"Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine ."
<p>1795,"Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine ."
<p>1796,"Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine ."
<p>1797,"Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine ."
<p>1798,"Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine ."
<p>1799,HMG-CoA_Reductase_Inhibitors : Simvastatin ( CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
<p>1800,HMG-CoA_Reductase_Inhibitors : Simvastatin ( CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
<p>1801,"Cardiovasculars: Cardiac_glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity."
<p>1802,"Cardiovasculars: Cardiac_glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity."
<p>1803,Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70</p> after one day.
<p>1804,Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70</p> after one day.
<p>1805,"On administration of oral amiodarone , the need for digitalis therapy should be reviewed and the dose reduced by approximately 50</p> or discontinued."
<p>1806,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1807,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1808,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1809,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1810,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1811,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1812,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1813,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1814,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1815,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1816,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1817,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1818,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1819,"Antiarrhythmics : Other antiarrhythmic drugs, such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone ."
<p>1820,"There have been case reports of increased steady-state levels of quinidine , procainamide , and phenytoin during concomitant therapy with amiodarone ."
<p>1821,"There have been case reports of increased steady-state levels of quinidine , procainamide , and phenytoin during concomitant therapy with amiodarone ."
<p>1822,"There have been case reports of increased steady-state levels of quinidine , procainamide , and phenytoin during concomitant therapy with amiodarone ."
<p>1823,Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33</p> after two days.
<p>1824,Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33</p> after two days.
<p>1825,"Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55</p> and 33%, respectively."
<p>1826,"Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55</p> and 33%, respectively."
<p>1827,"Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55</p> and 33%, respectively."
<p>1828,Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone .
<p>1829,Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone ;
<p>1830,"because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly."
<p>1831,Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone .
<p>1832,Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone .
<p>1833,"The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted."
<p>1834,"In amiodarone -treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose."
<p>1835,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1836,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1837,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1838,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1839,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1840,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1841,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1842,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1843,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1844,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1845,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1846,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1847,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1848,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1849,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1850,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1851,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1852,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1853,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1854,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1855,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1856,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1857,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1858,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1859,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1860,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1861,"Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents (e,g,, propranolol , a CYP3A4 inhibitor) or calcium_channel antagonists (e,g,, verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;"
<p>1862,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1863,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1864,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1865,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1866,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1867,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1868,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1869,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1870,Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
<p>1871,"Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100</p> after # to # days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely."
<p>1872,"Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100</p> after # to # days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely."
<p>1873,"Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100</p> after # to # days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely."
<p>1874,Some drugs /substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
<p>1875,Some drugs /substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
<p>1876,Some drugs /substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
<p>1877,Reported examples of this interaction include the following: Antibiotics : Rifampin is a potent inducer of CYP3A4 .
<p>1878,Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone .
<p>1879,Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone .
<p>1880,Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone .
<p>1881,"Since amiodarone is a substrate for CYP3A4 , there is the potential that the use of St, John s Wort in patients receiving amiodarone could result in reduced amiodarone levels."
<p>1882,"Other reported interactions with amiodarone : Fentanyl ( CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output."
<p>1883,"Other reported interactions with amiodarone : Fentanyl ( CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output."
<p>1884,Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .
<p>1885,Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .
<p>1886,Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .
<p>1887,Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .
<p>1888,Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .
<p>1889,"Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone ."
<p>1890,Dextromethorphan is a substrate for both CYP2D6 and CYP3A4 .
<p>1891,Dextromethorphan is a substrate for both CYP2D6 and CYP3A4 .
<p>1892,Dextromethorphan is a substrate for both CYP2D6 and CYP3A4 .
<p>1893,Amiodarone inhibits CYP2D6 .
<p>1894,Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1 /2.
<p>1895,Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1 /2.
<p>1896,Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1 /2.
<p>1897,"There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones , macrolide_antibiotics , or azoles were administered concomitantly."
<p>1898,"There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones , macrolide_antibiotics , or azoles were administered concomitantly."
<p>1899,"In addition to the interactions noted above, chronic ( # weeks) oral Cordarone administration impairs metabolism of phenytoin , dextromethorphan , and methotrexate ."
<p>1900,"In addition to the interactions noted above, chronic ( # weeks) oral Cordarone administration impairs metabolism of phenytoin , dextromethorphan , and methotrexate ."
<p>1901,"In addition to the interactions noted above, chronic ( # weeks) oral Cordarone administration impairs metabolism of phenytoin , dextromethorphan , and methotrexate ."
<p>1902,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."
<p>1903,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."
<p>1904,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."
<p>1905,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."
<p>1906,"cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type_1C_antiarrhythmics  propafenone and flecainide )."
<p>1907,"While all the selective serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."
<p>1908,"While all the selective serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."
<p>1909,"While all the selective serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."
<p>1910,"While all the selective serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."
<p>1911,"While all the selective serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."
<p>1912,"While all the selective serotonin_reuptake_inhibitors ( SSRIs ), e,g,, fluoxetine , sertraline , and paroxetine , inhibit P450 2D6, they may vary in the extent of inhibition."
<p>1913,The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
<p>1914,The extent to which SSRI - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
<p>1915,"Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other."
<p>1916,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1917,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1918,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1919,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1920,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1921,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1922,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1923,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1924,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1925,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1926,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1927,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1928,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1929,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1930,"and disulfiram When amitriptyline_HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required."
<p>1931,"Hyperpyrexia has been reported when amitriptyline_HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather."
<p>1932,"Hyperpyrexia has been reported when amitriptyline_HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather."
<p>1933,"Hyperpyrexia has been reported when amitriptyline_HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather."
<p>1934,Paralytic ileus may occur in patients taking tricyclic_antidepressants in combination with anticholinergic -type drugs.
<p>1935,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic_antidepressants , thereby delaying elimination and increasing steady-state concentrations of these drugs ."
<p>1936,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic_antidepressants , thereby delaying elimination and increasing steady-state concentrations of these drugs ."
<p>1937,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic_antidepressants , thereby delaying elimination and increasing steady-state concentrations of these drugs ."
<p>1938,Clinically significant effects have been reported with the tricyclic_antidepressants when used concomitantly with cimetidine .
<p>1939,"Increases in plasma levels of tricyclic_antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen."
<p>1940,"Increases in plasma levels of tricyclic_antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen."
<p>1941,"Increases in plasma levels of tricyclic_antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen."
<p>1942,"Increases in plasma levels of tricyclic_antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen."
<p>1943,"Increases in plasma levels of tricyclic_antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen."
<p>1944,"Increases in plasma levels of tricyclic_antidepressants , and in the frequency and severity of side effects, particularly anticholinergic , have been reported when cimetidine was added to the drug regimen."
<p>1945,Discontinuation of cimetidine in well-controlled patients receiving tricyclic_antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants .
<p>1946,Discontinuation of cimetidine in well-controlled patients receiving tricyclic_antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants .
<p>1947,Discontinuation of cimetidine in well-controlled patients receiving tricyclic_antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants .
<p>1948,Discontinuation of cimetidine in well-controlled patients receiving tricyclic_antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants .
<p>1949,Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and # - # mg of amitriptyline_HCl .
<p>1950,"When administered concurrently, the following drugs may interact with amphotericin_B : Antineoplastic_agents : may enhance the potential for renal toxicity, bronchospasm and hypotension."
<p>1951,Corticosteroids and Corticotropin ( ACTH ): may potentiate amphotericin_B - induced hypokalemia which may predispose the patient to cardiac dysfunction.
<p>1952,Corticosteroids and Corticotropin ( ACTH ): may potentiate amphotericin_B - induced hypokalemia which may predispose the patient to cardiac dysfunction.
<p>1953,Corticosteroids and Corticotropin ( ACTH ): may potentiate amphotericin_B - induced hypokalemia which may predispose the patient to cardiac dysfunction.
<p>1954,Corticosteroids and Corticotropin ( ACTH ): may potentiate amphotericin_B - induced hypokalemia which may predispose the patient to cardiac dysfunction.
<p>1955,Corticosteroids and Corticotropin ( ACTH ): may potentiate amphotericin_B - induced hypokalemia which may predispose the patient to cardiac dysfunction.
<p>1956,Digitalis_glycosides : amphotericin_B -induced hypokalemia may potentiate digitalis toxicity.
<p>1957,Digitalis_glycosides : amphotericin_B -induced hypokalemia may potentiate digitalis toxicity.
<p>1958,"Flucytosine : while a synergistic relationship with amphotericin_B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion."
<p>1959,"Flucytosine : while a synergistic relationship with amphotericin_B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion."
<p>1960,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1961,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1962,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1963,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1964,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1965,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1966,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1967,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1968,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1969,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1970,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1971,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1972,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1973,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1974,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1975,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1976,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1977,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1978,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1979,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1980,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1981,"Imidazoles (e, g,, ketoconazole , miconazole , clotrimazole , fluconazole , etc,): in vitro and animal studies with the combination of amphotericin_B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin_B ."
<p>1982,"Skeletal_muscle_relaxants : amphotericin_B -induced hypokalemia may enhance the curariform effect of skeletal_muscle_relaxants (e,g,, tubocurarine )."
<p>1983,"Skeletal_muscle_relaxants : amphotericin_B -induced hypokalemia may enhance the curariform effect of skeletal_muscle_relaxants (e,g,, tubocurarine )."
<p>1984,"Skeletal_muscle_relaxants : amphotericin_B -induced hypokalemia may enhance the curariform effect of skeletal_muscle_relaxants (e,g,, tubocurarine )."
<p>1985,"Skeletal_muscle_relaxants : amphotericin_B -induced hypokalemia may enhance the curariform effect of skeletal_muscle_relaxants (e,g,, tubocurarine )."
<p>1986,Leukocyte_transfusions : acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin_B and leukocyte_transfusions .
<p>1987,Leukocyte_transfusions : acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin_B and leukocyte_transfusions .
<p>1988,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1989,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1990,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1991,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1992,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1993,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1994,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1995,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1996,"Bacteriostatic_Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins ."
<p>1997,Probenecid : May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
<p>1998,Probenecid : May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
<p>1999,"Drug/Laboratory Test Interaction After treatment with ampicillin , a false-positive reaction for glucose in the urine may occur with copper_sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP."
<p>2000,HIV_Protease_Inhibitors : The effect of amprenavir on total drug concentrations of other HIV_protease_inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
<p>2001,"Indinavir steady-state Cmax, A,C, and Cmin were decreased by 22</p>, 38%, and 27%, respectively, by concomitant amprenavir ."
<p>2002,"Saquinavir steady-state Cmax, A,C, and Cmin were increased 21</p>, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir ."
<p>2003,"Nelfinavir steady-state Cmax, A,C, and Cmin were increased by 12</p>, 15%, and 14%, respectively, by concomitant amprenavir ."
<p>2004,Methadone : Coadministration of amprenavir and methadone can decrease plasma levels of methadone .
<p>2005,Methadone : Coadministration of amprenavir and methadone can decrease plasma levels of methadone .
<p>2006,Methadone : Coadministration of amprenavir and methadone can decrease plasma levels of methadone .
<p>2007,"Coadministration of amprenavir and methadone as compared to a non-matched historical control group resulted in a 30</p>, 27%, and 25% decrease in serum amprenavir AUC, Cmax, and cmin, respectively."
<p>2008,"Coadministration of amprenavir and methadone as compared to a non-matched historical control group resulted in a 30</p>, 27%, and 25% decrease in serum amprenavir AUC, Cmax, and Cmin, respectively."
<p>2009,"Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients."
<p>2010,Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
<p>2011,"For comprehensive information concerning laboratory test alterations associated with ritonavir , physicians should refer to the complete prescribing information for NORVIR ( ritonavir )."
<p>2012,Taking amyl_nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
<p>2013,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2014,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2015,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2016,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2017,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2018,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2019,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2020,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2021,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2022,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2023,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2024,"In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin ."
<p>2025,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2026,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2027,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2028,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2029,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2030,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2031,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol ."
<p>2032,An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single # mg dose of aspirin was generally well tolerated.
<p>2033,No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic_acid were observed.
<p>2034,"Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin ."
<p>2035,"It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine , and such medicinal products could theoretically adversely influence the clearance of anagrelide ."
<p>2036,"Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e,g, theophylline ."
<p>2037,"The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and cilostazol may be exacerbated by anagrelide ."
<p>2038,"The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and cilostazol may be exacerbated by anagrelide ."
<p>2039,"The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and cilostazol may be exacerbated by anagrelide ."
<p>2040,"The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and cilostazol may be exacerbated by anagrelide ."
<p>2041,"The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and cilostazol may be exacerbated by anagrelide ."
<p>2042,"There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption."
<p>2043,Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
<p>2044,"In a study in which patients with active RA were treated for up to # weeks with concurrent Kineret and etanercept therapy, a 7</p> rate of serious infections was observed, which was higher than that observed with etanercept alone (0%)."
<p>2045,"In a study in which patients with active RA were treated for up to # weeks with concurrent Kineret and etanercept therapy, a 7</p> rate of serious infections was observed, which was higher than that observed with etanercept alone (0%)."
<p>2046,Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC # x 109/L).
<p>2047,Anastrozole did not alter the pharmacokinetics of antipyrine .
<p>2048,"Although there have been no formal interaction studies other than with antipyrine , based on these in vivo and in vitro studies, it is unlikely that co-administration of a # mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs."
<p>2049,An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
<p>2050,An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
<p>2051,"At a median follow-up of # months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation."
<p>2052,"At a median follow-up of # months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation."
<p>2053,"Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY  Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections)."
<p>2054,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27</p> compared with those achieved with anastrozole alone.
<p>2055,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27</p> compared with those achieved with anastrozole alone.
<p>2056,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27</p> compared with those achieved with anastrozole alone.
<p>2057,Estrogen -containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
<p>2058,"Caution should be observed when anileridine is coadministered with other opioids , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression."
<p>2059,"Caution should be observed when anileridine is coadministered with other opioids , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression."
<p>2060,"Caution should be observed when anileridine is coadministered with other opioids , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression."
<p>2061,"Caution should be observed when anileridine is coadministered with other opioids , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression."
<p>2062,"For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin_K , the net effects are unpredictable."
<p>2063,"For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin_K , the net effects are unpredictable."
<p>2064,"For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin_K , the net effects are unpredictable."
<p>2065,"Chloral_hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect."
<p>2066,"Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical_steroids ;"
<p>2067,"Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: alcohol *;"
<p>2068,salicylates ; sulfinpyrazone ;
<p>2069,trimethoprim / sulfamethoxazole ;
<p>2070,"Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic_agents , eg, tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver."
<p>2071,"Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic_agents , eg, tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver."
<p>2072,"Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic_agents , eg, tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver."
<p>2073,"Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic_agents , eg, tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver."
<p>2074,"Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic_agents , eg, tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver."
<p>2075,"Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic_agents , eg, tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver."
<p>2076,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2077,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2078,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2079,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2080,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2081,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2082,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2083,"Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin , toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently."
<p>2084,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2085,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2086,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2087,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2088,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2089,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2090,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2091,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2092,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2093,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2094,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2095,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2096,"Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic_agents ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal_anti-inflammatory_drugs , dipyridamole , hydrochloroquine , clofibrate , dextran ) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations."
<p>2097,The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet_medication and anticoagulant_medication must be weighed against an increased risk of inducing hemorrhage.
<p>2098,"Drug/Laboratory Test Interferences: Dicumarol and indanedione_anticoagulants , including anisindione , or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests."
<p>2099,"Drug/Laboratory Test Interferences: Dicumarol and indanedione_anticoagulants , including anisindione , or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests."
<p>2100,"Drug/Laboratory Test Interferences: Dicumarol and indanedione_anticoagulants , including anisindione , or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests."
<p>2101,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2102,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2103,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2104,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2105,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2106,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2107,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2108,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2109,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2110,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2111,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2112,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2113,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2114,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2115,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2116,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2117,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2118,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2119,"5HT3_Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3_antagonist_class (including, for example, ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated ."
<p>2120,"Antihypertensive_Medication s and Vasodilators : The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive_medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10</p> vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%."
<p>2121,"Antihypertensive_Medication s and Vasodilators : The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive_medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10</p> vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%."
<p>2122,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2123,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2124,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2125,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2126,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2127,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2128,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2129,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2130,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2131,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2132,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2133,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2134,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2135,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2136,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2137,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2138,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2139,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2140,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2141,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2142,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2143,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2144,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2145,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2146,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2147,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2148,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2149,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2150,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2151,"Dopamine_Antagonists : Since apomorphine is a dopamine_agonist , it is possible that dopamine_antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN ."
<p>2152,"Patients with major psychotic disorders, treated with neuroleptics , should be treated with dopamine_agonists only if the potential benefits outweigh the risks."
<p>2153,"Apraclonidine should not be used in patients receiving MAO_inhibitors ,."
<p>2154,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE #</p> Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered."
<p>2155,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE #</p> Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered."
<p>2156,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE #</p> Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered."
<p>2157,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE #</p> Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered."
<p>2158,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE #</p> Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered."
<p>2159,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE #</p> Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS_depressants ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered."
<p>2160,Tricyclic_antidepressants have been reported to blunt the hypotensive effect of systemic clonidine .
<p>2161,An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
<p>2162,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives , and cardiac_glycosides is advised."
<p>2163,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives , and cardiac_glycosides is advised."
<p>2164,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives , and cardiac_glycosides is advised."
<p>2165,"Aprepitant has been shown to induce the metabolism of S(-)_warfarin and tolbutamide , which are metabolized through CYP2C9."
<p>2166,"Aprepitant has been shown to induce the metabolism of S(-)_warfarin and tolbutamide , which are metabolized through CYP2C9."
<p>2167,"Aprepitant has been shown to induce the metabolism of S(-)_warfarin and tolbutamide , which are metabolized through CYP2C9."
<p>2168,"Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin , may result in lower plasma concentrations of these drugs."
<p>2169,"Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study."
<p>2170,"Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study."
<p>2171,"5-HT3_antagonists : In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron ."
<p>2172,"5-HT3_antagonists : In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron ."
<p>2173,"5-HT3_antagonists : In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron ."
<p>2174,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2175,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2176,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2177,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2178,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2179,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2180,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2181,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2182,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2183,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2184,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2185,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2186,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2187,"Corticosteroids : Dexamethasone : Aprepitant , when given as a regimen of 125mg with dexamethasone coadministered orally as # mg on Day 1, and Aprepitant when given as # mg/day with dexamethasone coadministered orally as # mg on Days # through 5, increased the AUC of dexamethasone , a CYP3A4 substrate by #-fold, on Days # and 5."
<p>2188,"The oral dexamethasone doses should be reduced by approximately 50</p> when coadministered with Aprepitant , to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant ."
<p>2189,"The oral dexamethasone doses should be reduced by approximately 50</p> when coadministered with Aprepitant , to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant ."
<p>2190,"The oral dexamethasone doses should be reduced by approximately 50</p> when coadministered with Aprepitant , to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant ."
<p>2191,"The oral dexamethasone doses should be reduced by approximately 50</p> when coadministered with Aprepitant , to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant ."
<p>2192,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50</p> reduction of the dose of dexamethasone .
<p>2193,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50</p> reduction of the dose of dexamethasone .
<p>2194,"Aprepitant , when given as a regimen of # mg on Day # and # mg/day on Days # and 3, increased the AUC of methylprednisolone , a CYP3A4 substrate, by #-fold on Day # and by #-fold on Day 3, when methylprednisolone was coadministered intravenously as # mg on Day # and orally as # mg on Days # and 3."
<p>2195,"Aprepitant , when given as a regimen of # mg on Day # and # mg/day on Days # and 3, increased the AUC of methylprednisolone , a CYP3A4 substrate, by #-fold on Day # and by #-fold on Day 3, when methylprednisolone was coadministered intravenously as # mg on Day # and orally as # mg on Days # and 3."
<p>2196,"The IV methylprednisolone dose should be reduced by approximately 25</p>, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant ."
<p>2197,"The IV methylprednisolone dose should be reduced by approximately 25</p>, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant ."
<p>2198,"The IV methylprednisolone dose should be reduced by approximately 25</p>, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant ."
<p>2199,"The IV methylprednisolone dose should be reduced by approximately 25</p>, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant ."
<p>2200,"The IV methylprednisolone dose should be reduced by approximately 25</p>, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant ."
<p>2201,"The IV methylprednisolone dose should be reduced by approximately 25</p>, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant ."
<p>2202,Warfarin : A single 125-mg dose of Aprepitant was administered on Day # and # mg/day on Days # and # to healthy subjects who were stabilized on chronic warfarin therapy.
<p>2203,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2204,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2205,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2206,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2207,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2208,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2209,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2210,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2211,"Although there was no effect of Aprepitant on the plasma AUC of R(+)_warfarin or S(-)_warfarin determined on Day 3, there was a 34</p> decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) # days after completion of dosing with Aprepitant ."
<p>2212,"In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at # to # days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle."
<p>2213,"Tolbutamide : Aprepitant , when given as # mg on Day # and # mg/day on Days # and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23</p> on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide # mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."
<p>2214,"Tolbutamide : Aprepitant , when given as # mg on Day # and # mg/day on Days # and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23</p> on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide # mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."
<p>2215,"Tolbutamide : Aprepitant , when given as # mg on Day # and # mg/day on Days # and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23</p> on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide # mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."
<p>2216,"Tolbutamide : Aprepitant , when given as # mg on Day # and # mg/day on Days # and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23</p> on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide # mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."
<p>2217,"Tolbutamide : Aprepitant , when given as # mg on Day # and # mg/day on Days # and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23</p> on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide # mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."
<p>2218,"Tolbutamide : Aprepitant , when given as # mg on Day # and # mg/day on Days # and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23</p> on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide # mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."
<p>2219,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2220,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2221,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2222,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2223,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2224,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2225,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2226,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2227,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2228,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2229,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2230,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2231,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2232,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2233,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2234,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2235,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2236,"Oral contraceptives : Aprepitant , when given once daily for # days as a 100-mg capsule with an oral contraceptive containing # mcg of ethinyl_estradiol and # mg of norethindrone , decreased the AUC of ethinyl_estradiol by 43</p>, and decreased the AUC of norethindrone by 8%;"
<p>2237,"therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced."
<p>2238,"Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used."
<p>2239,"Midazolam : Aprepitant increased the AUC of midazolam , a sensitive CYP3A4 substrate, by #-fold on Day # and #-fold on Day 5, when a single oral dose of midazolam # mg was coadministered on Day # and Day # of a regimen of Aprepitant # mg on Day # and # mg/day on Days # through 5."
<p>2240,"Midazolam : Aprepitant increased the AUC of midazolam , a sensitive CYP3A4 substrate, by #-fold on Day # and #-fold on Day 5, when a single oral dose of midazolam # mg was coadministered on Day # and Day # of a regimen of Aprepitant # mg on Day # and # mg/day on Days # through 5."
<p>2241,"Midazolam : Aprepitant increased the AUC of midazolam , a sensitive CYP3A4 substrate, by #-fold on Day # and #-fold on Day 5, when a single oral dose of midazolam # mg was coadministered on Day # and Day # of a regimen of Aprepitant # mg on Day # and # mg/day on Days # through 5."
<p>2242,"Midazolam : Aprepitant increased the AUC of midazolam , a sensitive CYP3A4 substrate, by #-fold on Day # and #-fold on Day 5, when a single oral dose of midazolam # mg was coadministered on Day # and Day # of a regimen of Aprepitant # mg on Day # and # mg/day on Days # through 5."
<p>2243,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2244,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2245,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2246,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2247,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2248,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2249,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2250,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2251,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 ( alprazolam , triazolam ) should be considered when coadministering these agents with Aprepitant ."
<p>2252,"In another study with intravenous administration of midazolam , Aprepitant was given as # mg on Day # and # mg/day on Days # and 3, and midazolam # mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15."
<p>2253,"In another study with intravenous administration of midazolam , Aprepitant was given as # mg on Day # and # mg/day on Days # and 3, and midazolam # mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15."
<p>2254,"In another study with intravenous administration of midazolam , Aprepitant was given as # mg on Day # and # mg/day on Days # and 3, and midazolam # mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15."
<p>2255,"In another study with intravenous administration of midazolam , Aprepitant was given as # mg on Day # and # mg/day on Days # and 3, and midazolam # mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15."
<p>2256,Aprepitant increased the AUC of midazolam by 25</p> on Day # and decreased the AUC of midazolam by 19% on Day # relative to the dosing of Aprepitant on Days # through 3.
<p>2257,Aprepitant increased the AUC of midazolam by 25</p> on Day # and decreased the AUC of midazolam by 19% on Day # relative to the dosing of Aprepitant on Days # through 3.
<p>2258,Aprepitant increased the AUC of midazolam by 25</p> on Day # and decreased the AUC of midazolam by 19% on Day # relative to the dosing of Aprepitant on Days # through 3.
<p>2259,Aprepitant increased the AUC of midazolam by 25</p> on Day # and decreased the AUC of midazolam by 19% on Day # relative to the dosing of Aprepitant on Days # through 3.
<p>2260,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2261,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2262,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2263,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2264,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2265,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2266,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e,g,, ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) should be approached with caution."
<p>2267,"Because moderate CYP3A4 inhibitors (e,g,, diltiazem ) result in 2-fold increase in plasma concentrations of aprepitant , concomitant administration should also be approached with caution."
<p>2268,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2269,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2270,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2271,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2272,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2273,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2274,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2275,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2276,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e,g,, rifampin , carbamazepine , phenytoin ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant ."
<p>2277,"Ketoconazole : When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of # mg/day of ketoconazole , a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold."
<p>2278,"Ketoconazole : When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of # mg/day of ketoconazole , a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold."
<p>2279,"Ketoconazole : When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of # mg/day of ketoconazole , a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold."
<p>2280,"Rifampin : When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of # mg/day of rifampin , a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold."
<p>2281,"Rifampin : When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of # mg/day of rifampin , a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold."
<p>2282,"Diltiazem : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to # mg of the capsule formulation, with diltiazem # mg # times daily for # days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous #-fold increase of diltiazem AUC."
<p>2283,"Diltiazem : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to # mg of the capsule formulation, with diltiazem # mg # times daily for # days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous #-fold increase of diltiazem AUC."
<p>2284,"Diltiazem : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to # mg of the capsule formulation, with diltiazem # mg # times daily for # days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous #-fold increase of diltiazem AUC."
<p>2285,"Diltiazem : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to # mg of the capsule formulation, with diltiazem # mg # times daily for # days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous #-fold increase of diltiazem AUC."
<p>2286,"Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to # mg or # mg of the capsule formulation, with paroxetine # mg once daily, resulted in a decrease in AUC by approximately 25</p> and Cmax, by approximately 20% of both aprepitant and paroxetine ."
<p>2287,"Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to # mg or # mg of the capsule formulation, with paroxetine # mg once daily, resulted in a decrease in AUC by approximately 25</p> and Cmax, by approximately 20% of both aprepitant and paroxetine ."
<p>2288,"Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to # mg or # mg of the capsule formulation, with paroxetine # mg once daily, resulted in a decrease in AUC by approximately 25</p> and Cmax, by approximately 20% of both aprepitant and paroxetine ."
<p>2289,"Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to # mg or # mg of the capsule formulation, with paroxetine # mg once daily, resulted in a decrease in AUC by approximately 25</p> and Cmax, by approximately 20% of both aprepitant and paroxetine ."
<p>2290,"Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to # mg or # mg of the capsule formulation, with paroxetine # mg once daily, resulted in a decrease in AUC by approximately 25</p> and Cmax, by approximately 20% of both aprepitant and paroxetine ."
<p>2291,"Paroxetine : Coadministration of once daily doses of aprepitant , as a tablet formulation comparable to # mg or # mg of the capsule formulation, with paroxetine # mg once daily, resulted in a decrease in AUC by approximately 25</p> and Cmax, by approximately 20% of both aprepitant and paroxetine ."
<p>2292,Beta-adrenergic_blocking_agents : concurrent use may blunt the response to arbutamine .
<p>2293,Beta-adrenergic_blocking_agents should be withdrawn at least # hours before conducting an arbutamine -mediated stress test.
<p>2294,"Antiarrhythmic_agents,_class_I (such as flecainide , lidocaine , or quinidine ): concurrent use with arbutamine may have a proarrhythmic effect."
<p>2295,"Antiarrhythmic_agents,_class_I (such as flecainide , lidocaine , or quinidine ): concurrent use with arbutamine may have a proarrhythmic effect."
<p>2296,"Antiarrhythmic_agents,_class_I (such as flecainide , lidocaine , or quinidine ): concurrent use with arbutamine may have a proarrhythmic effect."
<p>2297,"Antiarrhythmic_agents,_class_I (such as flecainide , lidocaine , or quinidine ): concurrent use with arbutamine may have a proarrhythmic effect."
<p>2298,"Antidepressants ( tricyclic ), atropine or other anticholinergic_agents , or digitalis_glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects."
<p>2299,"Antidepressants ( tricyclic ), atropine or other anticholinergic_agents , or digitalis_glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects."
<p>2300,"Antidepressants ( tricyclic ), atropine or other anticholinergic_agents , or digitalis_glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects."
<p>2301,"Antidepressants ( tricyclic ), atropine or other anticholinergic_agents , or digitalis_glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects."
<p>2302,"Antidepressants ( tricyclic ), atropine or other anticholinergic_agents , or digitalis_glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects."
<p>2303,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2304,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2305,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2306,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2307,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2308,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2309,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2310,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2311,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2312,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2313,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2314,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2315,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2316,"Anticoagulants including coumarin derivatives, indandione derivatives, and platelet_aggregation_inhibitors such as nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin ."
<p>2317,"If additional adrenergic_drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated."
<p>2318,"When paroxetine , a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered."
<p>2319,"Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of adrenergic_agonists ."
<p>2320,"Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of adrenergic_agonists ."
<p>2321,"Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of adrenergic_agonists ."
<p>2322,"Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of adrenergic_agonists ."
<p>2323,"Concomitant treatment with methylxanthines ( aminophylline , theophylline ), steroids , or diuretics may potentiate any hypokalemic effect of adrenergic_agonists ."
<p>2324,"The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded."
<p>2325,"The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded."
<p>2326,"The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded."
<p>2327,"The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded."
<p>2328,"The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded."
<p>2329,"The ECG changes and/or hypokalemia that may result from the administration of non-potassium_sparing_diuretics (such as loop_diuretics or thiazide_diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded."
<p>2330,"Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium_sparing_diuretics ."
<p>2331,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2332,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2333,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2334,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2335,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2336,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2337,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2338,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2339,"BROVANA , as with other beta2-agonists , should be administered with extreme caution to patients being treated with monoamine_oxidase_inhibitors , tricyclic_antidepressants , or drugs known to prolong the QTc interval because the action of adrenergic_agonists on the cardiovascular system may be potentiated by these agents."
<p>2340,"The concurrent use of intravenously or orally administered methylxanthines (e,g,, aminophylline , theophylline ) by patients receiving BROVANA has not been completely evaluated."
<p>2341,"The concurrent use of intravenously or orally administered methylxanthines (e,g,, aminophylline , theophylline ) by patients receiving BROVANA has not been completely evaluated."
<p>2342,"The concurrent use of intravenously or orally administered methylxanthines (e,g,, aminophylline , theophylline ) by patients receiving BROVANA has not been completely evaluated."
<p>2343,"In two combined 12-week placebo controlled trials that included BROVANA doses of # mcg twice daily, # mcg twice daily, and # mcg once daily, # of # BROVANA -treated subjects received concomitant theophylline at study entry."
<p>2344,"In two combined 12-week placebo controlled trials that included BROVANA doses of # mcg twice daily, # mcg twice daily, and # mcg once daily, # of # BROVANA -treated subjects received concomitant theophylline at study entry."
<p>2345,"In a 12-month controlled trial that included a # mcg once daily BROVANA dose, # of the # BROVANA -treated subjects received concomitant theophylline at study entry."
<p>2346,"In a 12-month controlled trial that included a # mcg once daily BROVANA dose, # of the # BROVANA -treated subjects received concomitant theophylline at study entry."
<p>2347,Beta-adrenergic_receptor_antagonists ( beta-blockers ) and BROVANA may interfere with the effect of each other when administered concurrently.
<p>2348,Beta-adrenergic_receptor_antagonists ( beta-blockers ) and BROVANA may interfere with the effect of each other when administered concurrently.
<p>2349,"Beta-blockers not only block the therapeutic effects of beta-agonists , but may produce severe bronchospasm in COPD patients."
<p>2350,"Heparin : Since heparin is contraindicated in patients with heparin -induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication."
<p>2351,"Heparin : Since heparin is contraindicated in patients with heparin -induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication."
<p>2352,"Heparin : Since heparin is contraindicated in patients with heparin -induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication."
<p>2353,"However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy."
<p>2354,"However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy."
<p>2355,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2356,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2357,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2358,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2359,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2360,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2361,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2362,"Aspirin / Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (# mg orally given # and # hours prior to initiation of Argatroban # g/kg/min, over # hours) or acetaminophen (1000 mg orally given 12, # and # hours prior to, and # and # hours subsequent to, initiation of Argatroban # g/kg/min, over # hours)."
<p>2363,Oral anticoagulant_agents : Pharmacokinetic drug-drug interactions between Argatroban and warfarin (# mg single oral dose) have not been demonstrated.
<p>2364,"However, the concomitant use of Argatroban and warfarin (5# mg initial oral dose followed by #-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR)."
<p>2365,Thrombolytic_agents : The safety and effectiveness of Argatroban with thrombolytic_agents have not been established.
<p>2366,"Co-administration: Concomitant use of Argatroban with antiplatelet_agents , thrombolytics , and other anticoagulants may increase the risk of bleeding."
<p>2367,"Co-administration: Concomitant use of Argatroban with antiplatelet_agents , thrombolytics , and other anticoagulants may increase the risk of bleeding."
<p>2368,"Co-administration: Concomitant use of Argatroban with antiplatelet_agents , thrombolytics , and other anticoagulants may increase the risk of bleeding."
<p>2369,"Co-administration: Concomitant use of Argatroban with antiplatelet_agents , thrombolytics , and other anticoagulants may increase the risk of bleeding."
<p>2370,"Co-administration: Concomitant use of Argatroban with antiplatelet_agents , thrombolytics , and other anticoagulants may increase the risk of bleeding."
<p>2371,"Co-administration: Concomitant use of Argatroban with antiplatelet_agents , thrombolytics , and other anticoagulants may increase the risk of bleeding."
<p>2372,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally_acting_drugs and alcohol ."
<p>2373,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally_acting_drugs and alcohol ."
<p>2374,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally_acting_drugs and alcohol ."
<p>2375,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally_acting_drugs and alcohol ."
<p>2376,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally_acting_drugs and alcohol ."
<p>2377,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole , caution should be used when ABILIFY is taken in combination with other centrally_acting_drugs and alcohol ."
<p>2378,"1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive_agents ."
<p>2379,"Potential for Other Drugs to Affect ABILIFY  Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes."
<p>2380,"Agents that induce CYP3A4 (eg, carbamazepine ) could cause an increase in aripiprazole clearance and lower blood levels."
<p>2381,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2382,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2383,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2384,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2385,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2386,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2387,"Inhibitors of CYP3A4 (eg, ketoconazole ) or CYP2D6 (eg, quinidine , fluoxetine , or paroxetine ) can inhibit aripiprazole elimination and cause increased blood levels."
<p>2388,"Ketoconazole : Coadministration of ketoconazole (200 mg/day for # days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63</p> and 77%, respectively."
<p>2389,"Ketoconazole : Coadministration of ketoconazole (200 mg/day for # days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63</p> and 77%, respectively."
<p>2390,"Ketoconazole : Coadministration of ketoconazole (200 mg/day for # days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63</p> and 77%, respectively."
<p>2391,"Ketoconazole : Coadministration of ketoconazole (200 mg/day for # days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63</p> and 77%, respectively."
<p>2392,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose."
<p>2393,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose."
<p>2394,"Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for # days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112</p> but decreased the AUC of its active metabolite, dehydroaripiprazole , by 35%."
<p>2395,"Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for # days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112</p> but decreased the AUC of its active metabolite, dehydroaripiprazole , by 35%."
<p>2396,"Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for # days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112</p> but decreased the AUC of its active metabolite, dehydroaripiprazole , by 35%."
<p>2397,"Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for # days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112</p> but decreased the AUC of its active metabolite, dehydroaripiprazole , by 35%."
<p>2398,"Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for # days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112</p> but decreased the AUC of its active metabolite, dehydroaripiprazole , by 35%."
<p>2399,"Quinidine : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for # days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112</p> but decreased the AUC of its active metabolite, dehydroaripiprazole , by 35%."
<p>2400,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
<p>2401,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
<p>2402,"Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine , would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions."
<p>2403,"Carbamazepine : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70</p> decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole ."
<p>2404,"Carbamazepine : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70</p> decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole ."
<p>2405,"Carbamazepine : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70</p> decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole ."
<p>2406,"Carbamazepine : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70</p> decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole ."
<p>2407,"Carbamazepine : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70</p> decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole ."
<p>2408,"Carbamazepine : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70</p> decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole ."
<p>2409,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled."
<p>2410,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled."
<p>2411,"When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced."
<p>2412,"No clinically significant effect of famotidine , valproate , or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."
<p>2413,"No clinically significant effect of famotidine , valproate , or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."
<p>2414,"No clinically significant effect of famotidine , valproate , or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions)."
<p>2415,Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
<p>2416,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2417,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2418,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2419,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2420,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2421,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2422,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2423,"In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( dextromethorphan ), CYP2C9 ( warfarin ), CYP2C19 ( omeprazole , warfarin ), and CYP3A4 ( dextromethorphan ) substrates."
<p>2424,Alcohol : There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
<p>2425,Alcohol : There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
<p>2426,"As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY"
<p>2427,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2428,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2429,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2430,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2431,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2432,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2433,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2434,"Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e,g, certain antiarrhythmics or thioridazine ) or lead to electrolyte abnormalities (such as diuretics or amphotericin_B )."
<p>2435,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells# This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
<p>2436,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells# This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
<p>2437,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR , or during the period following ELSPAR therapy when plasma asparagine levels are below normal."
<p>2438,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR , or during the period following ELSPAR therapy when plasma asparagine levels are below normal."
<p>2439,"Uricosuric_Agents : Aspirin may decrease the effects of probenecid , sulfinpyrazone , and phenylbutazone ."
<p>2440,"Uricosuric_Agents : Aspirin may decrease the effects of probenecid , sulfinpyrazone , and phenylbutazone ."
<p>2441,"Uricosuric_Agents : Aspirin may decrease the effects of probenecid , sulfinpyrazone , and phenylbutazone ."
<p>2442,Corticosteroids : Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
<p>2443,"Pyrazolone_Derivatives ( phenylbutazone , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration."
<p>2444,"Pyrazolone_Derivatives ( phenylbutazone , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration."
<p>2445,"Pyrazolone_Derivatives ( phenylbutazone , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration."
<p>2446,"Pyrazolone_Derivatives ( phenylbutazone , oxyphenbutazone , and possibly dipyrone ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration."
<p>2447,Nonsteroidal_Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal_anti-inflammatory agents.
<p>2448,Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.
<p>2449,Phenobarbital : Decreases aspirin effectiveness by enzyme induction.
<p>2450,Phenytoin : Serum phenytoin levels may be increased by aspirin .
<p>2451,Propranolol : May decrease aspirins anti-inflammatory action by competing for the same receptors.
<p>2452,"Antacids : Enteric Coated Aspirin should not be given concurrently with antacids , since an increase in the pH of the stomach may effect the enteric coating of the tablets."
<p>2453,"Ketoconazole / Itraconazole , Macrolides , Including Erythromycin"
<p>2454,"Ketoconazole / Itraconazole , Macrolides , Including Erythromycin"
<p>2455,"Ketoconazole / Itraconazole , Macrolides , Including Erythromycin"
<p>2456,"Ketoconazole / Itraconazole , Macrolides , Including Erythromycin"
<p>2457,"Ketoconazole / Itraconazole , Macrolides , Including Erythromycin"
<p>2458,"Ketoconazole / Itraconazole , Macrolides , Including Erythromycin"
<p>2459,"Catecholamine-depleting drugs (eg, reserpine ) may have an additive effect when given with beta-blocking_agent s."
<p>2460,Calcium_channel_blockers may also have an additive effect when given with TENORMIN .
<p>2461,Beta_blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine .
<p>2462,"If the two drugs are coadministered, the beta_blocker should be withdrawn several days before the gradual withdrawal of clonidine ."
<p>2463,"If replacing clonidine by beta-blocker therapy, the introduction of beta_blockers should be delayed for several days after clonidine administration has stopped."
<p>2464,"If replacing clonidine by beta-blocker therapy, the introduction of beta_blockers should be delayed for several days after clonidine administration has stopped."
<p>2465,"If replacing clonidine by beta-blocker therapy, the introduction of beta_blockers should be delayed for several days after clonidine administration has stopped."
<p>2466,"If replacing clonidine by beta-blocker therapy, the introduction of beta_blockers should be delayed for several days after clonidine administration has stopped."
<p>2467,"If replacing clonidine by beta-blocker therapy, the introduction of beta_blockers should be delayed for several days after clonidine administration has stopped."
<p>2468,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin , may decrease the hypotensive effects of beta_blockers ."
<p>2469,Information on concurrent usage of atenolol and aspirin is limited.
<p>2470,"Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta_blockers in the acute myocardial infarction setting."
<p>2471,Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2_agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
<p>2472,Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2_agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
<p>2473,Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2_agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
<p>2474,Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2_agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
<p>2475,Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2_agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
<p>2476,Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2_agonists ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
<p>2477,"Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e,g,, paroxetine , fluoxetine , and quinidine ."
<p>2478,"Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e,g,, paroxetine , fluoxetine , and quinidine ."
<p>2479,"Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e,g,, paroxetine , fluoxetine , and quinidine ."
<p>2480,"In EM individuals treated with paroxetine or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."
<p>2481,"In EM individuals treated with paroxetine or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."
<p>2482,"In EM individuals treated with paroxetine or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."
<p>2483,"In EM individuals treated with paroxetine or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."
<p>2484,"In EM individuals treated with paroxetine or fluoxetine , the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."
<p>2485,"Antacid : When atorvastatin and Maalox_TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35</p>."
<p>2486,"Antacid : When atorvastatin and Maalox_TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35</p>."
<p>2487,"Antipyrine : Because atorvastatin does not affect the pharmacokinetics of antipyrine , interactions with other drugs metabolized via the same cytochrome isozymes are not expected."
<p>2488,"Antipyrine : Because atorvastatin does not affect the pharmacokinetics of antipyrine , interactions with other drugs metabolized via the same cytochrome isozymes are not expected."
<p>2489,"Antipyrine : Because atorvastatin does not affect the pharmacokinetics of antipyrine , interactions with other drugs metabolized via the same cytochrome isozymes are not expected."
<p>2490,Colestipol : Plasma concentrations of atorvastatin decreased approximately 25</p> when colestipol and atorvastatin were coadministered.
<p>2491,Colestipol : Plasma concentrations of atorvastatin decreased approximately 25</p> when colestipol and atorvastatin were coadministered.
<p>2492,"However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone."
<p>2493,Cimetidine : Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine .
<p>2494,"Digoxin : When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20</p>."
<p>2495,"Digoxin : When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20</p>."
<p>2496,"Erythromycin : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40</p> with coadministration of atorvastatin and erythromycin , a known inhibitor of cytochrome P450 3A4."
<p>2497,"Erythromycin : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40</p> with coadministration of atorvastatin and erythromycin , a known inhibitor of cytochrome P450 3A4."
<p>2498,"Erythromycin : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40</p> with coadministration of atorvastatin and erythromycin , a known inhibitor of cytochrome P450 3A4."
<p>2499,"Erythromycin : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40</p> with coadministration of atorvastatin and erythromycin , a known inhibitor of cytochrome P450 3A4."
<p>2500,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2501,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2502,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2503,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2504,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2505,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2506,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2507,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2508,Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl_estradiol by approximately 30</p> and 20%.
<p>2509,These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin .
<p>2510,Warfarin : Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
<p>2511,"Caution should be exercised if an HMG-CoA_reductase_inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole , spironolactone , and cimetidine ."
<p>2512,"Caution should be exercised if an HMG-CoA_reductase_inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole , spironolactone , and cimetidine ."
<p>2513,"Caution should be exercised if an HMG-CoA_reductase_inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole , spironolactone , and cimetidine ."
<p>2514,"The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone ."
<p>2515,"The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone ."
<p>2516,"The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone ."
<p>2517,"The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone ."
<p>2518,Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
<p>2519,Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
<p>2520,Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
<p>2521,Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
<p>2522,Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
<p>2523,Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON .
<p>2524,"Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin ."
<p>2525,"Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin ."
<p>2526,"Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin ."
<p>2527,"Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin ."
<p>2528,"Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin ."
<p>2529,No interaction trials have been conducted with MEPRON and rifabutin .
<p>2530,Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ;
<p>2531,"certain antibiotics , especially the aminoglycosides and polymyxins ;"
<p>2532,"certain antibiotics , especially the aminoglycosides and polymyxins ;"
<p>2533,"certain antibiotics , especially the aminoglycosides and polymyxins ;"
<p>2534,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2535,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2536,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2537,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2538,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2539,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2540,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2541,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2542,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2543,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2544,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2545,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2546,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2547,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2548,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2549,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2550,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2551,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2552,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2553,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2554,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2555,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2556,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2557,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2558,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2559,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2560,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2561,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2562,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2563,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2564,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2565,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2566,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2567,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2568,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2569,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2570,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2571,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2572,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2573,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2574,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2575,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2576,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2577,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2578,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2579,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2580,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2581,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2582,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2583,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2584,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2585,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2586,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2587,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2588,"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane ; isoflurane ; halothane ;certain antibiotics , especially the aminoglycosides and polymyxins ; lithium ; magnesium salts; procainamide ;and quinidine ."
<p>2589,"The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM ."
<p>2590,TRACRIUM should not be administered until a patient has recovered from succinylcholine -induced neuromuscular block.
<p>2591,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine ."
<p>2592,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine ."
<p>2593,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine ."
<p>2594,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine ."
<p>2595,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine ."
<p>2596,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine ."
<p>2597,The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime .
<p>2598,"Since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions."
<p>2599,"Auranofin should be avoided by patients with a history of serious reaction to any gold_medication , including Solganal and Myochrysine ."
<p>2600,"Auranofin should be avoided by patients with a history of serious reaction to any gold_medication , including Solganal and Myochrysine ."
<p>2601,"Auranofin should be avoided by patients with a history of serious reaction to any gold_medication , including Solganal and Myochrysine ."
<p>2602,"Auranofin should be avoided by patients with a history of serious reaction to any gold_medication , including Solganal and Myochrysine ."
<p>2603,"Auranofin should be avoided by patients with a history of serious reaction to any gold_medication , including Solganal and Myochrysine ."
<p>2604,"Auranofin should be avoided by patients with a history of serious reaction to any gold_medication , including Solganal and Myochrysine ."
<p>2605,"Auranofin should not be used together with penicillamine ( Depen , Cuprimine ), another arthritis medication."
<p>2606,"Auranofin should not be used together with penicillamine ( Depen , Cuprimine ), another arthritis medication."
<p>2607,"Auranofin should not be used together with penicillamine ( Depen , Cuprimine ), another arthritis medication."
<p>2608,MAO_inhibitors prolong and intensify the effects of antihistamines .
<p>2609,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2610,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2611,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2612,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2613,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2614,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2615,"Concomitant use of antihistamines with alcohol , tricyclic_antidepressants , barbiturates , or other central_nervous_system_depressants may have an additive effect."
<p>2616,"When sympathomimetic_drugs are given to patients receiving monoamine_oxidase_inhibitors , hypertensive reactions, including hypertensive crises, may occur."
<p>2617,"The antihypertensive effects of methyldopa , mecamylamine , reserpine , and veratrum_alkaloids may be reduced by sympathomimetics ."
<p>2618,"The antihypertensive effects of methyldopa , mecamylamine , reserpine , and veratrum_alkaloids may be reduced by sympathomimetics ."
<p>2619,"The antihypertensive effects of methyldopa , mecamylamine , reserpine , and veratrum_alkaloids may be reduced by sympathomimetics ."
<p>2620,"The antihypertensive effects of methyldopa , mecamylamine , reserpine , and veratrum_alkaloids may be reduced by sympathomimetics ."
<p>2621,Beta-adrenergic_blocking_agents may also interact with sympathomimetics .
<p>2622,Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis .
<p>2623,"Antacids increase the rate of absorption of pseudoephedrine , while kaolin decreases it."
<p>2624,"Antacids increase the rate of absorption of pseudoephedrine , while kaolin decreases it."
<p>2625,"Antacids increase the rate of absorption of pseudoephedrine , while kaolin decreases it."
<p>2626,Use with Allopurinol : The principal pathway for detoxification of azathioprine is inhibited by allopurinol .
<p>2627,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine , to approximately 1/3 to 1/4 the usual dose."
<p>2628,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine , to approximately 1/3 to 1/4 the usual dose."
<p>2629,Use with Angiotensin_Converting_Enzyme_Inhibitors : The use of angiotensin_converting_enzyme_inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
<p>2630,Co-administration of nelfinavir at steady-state with a single dose of azithromycin .
<p>2631,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x # mg tablets) results in increased azithromycin serum concentrations.
<p>2632,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x # mg tablets) results in increased azithromycin serum concentrations.
<p>2633,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir , close monitoring for known side effects of azithromycin , such as liver enzyme abnormalities and hearing impairment, is warranted."
<p>2634,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir , close monitoring for known side effects of azithromycin , such as liver enzyme abnormalities and hearing impairment, is warranted."
<p>2635,Azithromycin did not affect the prothrombin time response to a single dose of warfarin .
<p>2636,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly."
<p>2637,Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
<p>2638,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2639,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2640,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2641,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2642,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2643,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2644,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2645,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2646,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2647,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2648,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2649,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2650,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2651,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2652,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine ."
<p>2653,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin .
<p>2654,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin .
<p>2655,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin .
<p>2656,"Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations."
<p>2657,"Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations."
<p>2658,"Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin ."
<p>2659,"Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin ."
<p>2660,"Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin ."
<p>2661,"Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin ."
<p>2662,"Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin ."
<p>2663,Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
<p>2664,SIDE EFFECTS ( KEMSTRO ) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63</p>).
<p>2665,The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.
<p>2666,"No drug interaction studies have been conducted for COLAZAL , however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon."
<p>2667,"No drug interaction studies have been conducted for COLAZAL , however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon."
<p>2668,"No drug interaction studies have been conducted for COLAZAL , however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon."
<p>2669,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2670,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2671,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2672,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2673,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2674,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2675,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2676,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2677,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2678,"No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine , corticosteroids , and either azathioprine or mycophenolate_mofetil ."
<p>2679,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2680,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2681,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2682,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2683,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2684,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2685,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2686,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2687,"Total body clearance of Simulect was reduced by an average 22</p> and 51% when azathioprine and mycophenolate_mofetil , respectively, were added to a regimen consisting of cyclosporine , USP (MODIFIED) and corticosteroids ."
<p>2688,"Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate_mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h)."
<p>2689,"Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate_mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h)."
<p>2690,"Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate_mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h)."
<p>2691,"The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine , corticosteroids , cyclosporine , mycophenolate_mofetil , and muromonab-CD3 ."
<p>2692,"The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine , corticosteroids , cyclosporine , mycophenolate_mofetil , and muromonab-CD3 ."
<p>2693,"The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine , corticosteroids , cyclosporine , mycophenolate_mofetil , and muromonab-CD3 ."
<p>2694,"The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine , corticosteroids , cyclosporine , mycophenolate_mofetil , and muromonab-CD3 ."
<p>2695,"The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine , corticosteroids , cyclosporine , mycophenolate_mofetil , and muromonab-CD3 ."
<p>2696,"Albuterol , Antihistamines , antidiabetic_drugs , diuretics , digitalis ."
<p>2697,"Albuterol , Antihistamines , antidiabetic_drugs , diuretics , digitalis ."
<p>2698,"Albuterol , Antihistamines , antidiabetic_drugs , diuretics , digitalis ."
<p>2699,"Albuterol , Antihistamines , antidiabetic_drugs , diuretics , digitalis ."
<p>2700,"Diuretics : Patients on diuretics , especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin ."
<p>2701,"Diuretics : Patients on diuretics , especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin ."
<p>2702,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin .
<p>2703,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin .
<p>2704,Potassium Supplements and Potassium-Sparing_Diuretics Lotensin can attenuate potassium loss caused by thiazide_diuretics .
<p>2705,Potassium Supplements and Potassium-Sparing_Diuretics Lotensin can attenuate potassium loss caused by thiazide_diuretics .
<p>2706,"Potassium-sparing_diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplements can increase the risk of hyperkalemia."
<p>2707,"Potassium-sparing_diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplements can increase the risk of hyperkalemia."
<p>2708,"Potassium-sparing_diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplements can increase the risk of hyperkalemia."
<p>2709,Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants .
<p>2710,Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants .
<p>2711,Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants .
<p>2712,Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants .
<p>2713,Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants .
<p>2714,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .
<p>2715,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .
<p>2716,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .
<p>2717,Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE_inhibitors during therapy with lithium .
<p>2718,"If a diuretic is also used, the risk of lithium toxicity may be increased."
<p>2719,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2720,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2721,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2722,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2723,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2724,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2725,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2726,"Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide , chlorthalidone , furosemide , digoxin , propranolol , atenolol , naproxen , or cimetidine ."
<p>2727,"Lotensin has been used concomitantly with beta-adrenergic-blocking_agents , calcium-channel-blocking_agents , diuretics , digoxin , and hydralazine , without evidence of clinically important adverse interactions."
<p>2728,"Lotensin has been used concomitantly with beta-adrenergic-blocking_agents , calcium-channel-blocking_agents , diuretics , digoxin , and hydralazine , without evidence of clinically important adverse interactions."
<p>2729,"Lotensin has been used concomitantly with beta-adrenergic-blocking_agents , calcium-channel-blocking_agents , diuretics , digoxin , and hydralazine , without evidence of clinically important adverse interactions."
<p>2730,"Lotensin has been used concomitantly with beta-adrenergic-blocking_agents , calcium-channel-blocking_agents , diuretics , digoxin , and hydralazine , without evidence of clinically important adverse interactions."
<p>2731,"Lotensin has been used concomitantly with beta-adrenergic-blocking_agents , calcium-channel-blocking_agents , diuretics , digoxin , and hydralazine , without evidence of clinically important adverse interactions."
<p>2732,"Benazepril , like other ACE_inhibitors , has had less than additive effects with beta-adrenergic_blockers , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system"
<p>2733,"Benazepril , like other ACE_inhibitors , has had less than additive effects with beta-adrenergic_blockers , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system"
<p>2734,"Benazepril , like other ACE_inhibitors , has had less than additive effects with beta-adrenergic_blockers , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system"
<p>2735,"May interact with the following: cholestyramine , colestipol (use with thiazide_diuretics may prevent the diuretic from working properly;"
<p>2736,"May interact with the following: cholestyramine , colestipol (use with thiazide_diuretics may prevent the diuretic from working properly;"
<p>2737,"May interact with the following: cholestyramine , colestipol (use with thiazide_diuretics may prevent the diuretic from working properly;"
<p>2738,"May interact with the following: cholestyramine , colestipol (use with thiazide_diuretics may prevent the diuretic from working properly;"
<p>2739,"May interact with the following: cholestyramine , colestipol (use with thiazide_diuretics may prevent the diuretic from working properly;"
<p>2740,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2741,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2742,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2743,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2744,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2745,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2746,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2747,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2748,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2749,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2750,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2751,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2752,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2753,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2754,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2755,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2756,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2757,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2758,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2759,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2760,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2761,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2762,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2763,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2764,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2765,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2766,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2767,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2768,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2769,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2770,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2771,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2772,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2773,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2774,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2775,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2776,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2777,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2778,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2779,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2780,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2781,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2782,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2783,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2784,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2785,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2786,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2787,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2788,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2789,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2790,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2791,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2792,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2793,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2794,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2795,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2796,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2797,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2798,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2799,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2800,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2801,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2802,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2803,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2804,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2805,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2806,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2807,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2808,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2809,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2810,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2811,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2812,"Bentiromide may interact with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), local anesthetics (e,g,, benzocaine and lidocaine ), para-aminobenzoic_acid ( PABA )-containing preparations (e,g,, sunscreens and some multivitamins ), procainamide (e,g,, Pronestyl ), sulfonamides (sulfa medicines), thiazide_diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results)."
<p>2813,Hypertensive crises have resulted when sympathomimetic_amines have been used concomitantly within14 days following use of monoamine_oxidase_inhibitors .
<p>2814,DIDREX should not be used concomitantly with other CNS_stimulants .
<p>2815,Amphetamines may decrease the hypotensive effect of antihypertensives .
<p>2816,Amphetamines may enhance the effects of tricyclic_antidepressants .
<p>2817,Urinary_acidifying agents decrease blood levels and increase excretion of amphetamines .
<p>2818,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2819,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2820,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2821,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2822,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2823,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2824,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2825,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2826,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2827,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2828,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2829,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2830,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2831,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2832,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2833,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2834,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2835,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2836,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2837,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2838,"Benzthiazide may interact with alcohol , blood_thinner s, decongestant_drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications."
<p>2839,Antipsychotic_drugs such as phenothiazines or haloperidol ;
<p>2840,Antipsychotic_drugs such as phenothiazines or haloperidol ;
<p>2841,Antipsychotic_drugs such as phenothiazines or haloperidol ;
<p>2842,Nitrates : The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.
<p>2843,Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
<p>2844,Beta-blocking_Agents : The concomitant use of Bepridil and beta-blocking_agents has been well tolerated in patients with stable angina.
<p>2845,"Digoxin : In controlled studies in healthy volunteers, bepridil_hydrochloride either had no effect (one study) or was associated with modest increases, about 30</p> (two studies) in steady-state serum digoxin concentrations."
<p>2846,Limited clinical data in angina patients receiving concomitant bepridil_hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.
<p>2847,Oral Hypoglycemics : Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic_agents .
<p>2848,Oral Hypoglycemics : Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic_agents .
<p>2849,Oral Hypoglycemics : Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic_agents .
<p>2850,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2851,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2852,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2853,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2854,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2855,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2856,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2857,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2858,"In general, these are drugs that have one or more pharmacologic activities similar to bepridil_hydrochloride , including anti-arrhythmic_agents such as quinidine and procainamide , cardiac_glycosides and tricyclic_anti-depressants ."
<p>2859,Anti-arrhythmics and tricyclic_anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil_hydrochloride .
<p>2860,Anti-arrhythmics and tricyclic_anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil_hydrochloride .
<p>2861,Anti-arrhythmics and tricyclic_anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil_hydrochloride .
<p>2862,Cardiac_glycosides could exaggerate the depression of AV nodal conduction observed with bepridil_hydrochloride .
<p>2863,"The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine , nifedipine , chlorthalidone , and hydrochlorothiazide ."
<p>2864,"The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine , nifedipine , chlorthalidone , and hydrochlorothiazide ."
<p>2865,"The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine , nifedipine , chlorthalidone , and hydrochlorothiazide ."
<p>2866,"The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine , nifedipine , chlorthalidone , and hydrochlorothiazide ."
<p>2867,Concomitant administration of Kerlone with the oral anticoagulant  warfarin has been shown not to potentiate the anticoagulant effect of warfarin .
<p>2868,Concomitant administration of Kerlone with the oral anticoagulant  warfarin has been shown not to potentiate the anticoagulant effect of warfarin .
<p>2869,Concomitant administration of Kerlone with the oral anticoagulant  warfarin has been shown not to potentiate the anticoagulant effect of warfarin .
<p>2870,Concomitant administration of Kerlone with the oral anticoagulant  warfarin has been shown not to potentiate the anticoagulant effect of warfarin .
<p>2871,Concomitant administration of Kerlone with the oral anticoagulant  warfarin has been shown not to potentiate the anticoagulant effect of warfarin .
<p>2872,"Catecholamine-depleting drugs (e,g,, reserpine ) may have an additive effect when given with beta-blocking agents."
<p>2873,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine ."
<p>2874,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine ."
<p>2875,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine ."
<p>2876,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine ."
<p>2877,"Literature reports suggest that oral calcium_antagonists may be used in combination with beta-adrenergic_blocking_agents when heart function is normal, but should be avoided in patients with impaired cardiac function."
<p>2878,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic_blocking_agents when an oral calcium_antagonist was added to the treatment regimen."
<p>2879,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2880,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2881,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2882,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2883,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2884,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2885,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2886,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2887,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2888,"Hypotension was more likely to occur if the calcium_antagonist were a dihydropyridine_derivative , e,g,, nifedipine , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem ."
<p>2889,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks."
<p>2890,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks."
<p>2891,"In Study 1, patients with colorectal cancer were given irinotecan / 5-FU / leucovorin (bolus-IFL) with or without AVASTIN ."
<p>2892,"In Study 1, patients with colorectal cancer were given irinotecan / 5-FU / leucovorin (bolus-IFL) with or without AVASTIN ."
<p>2893,"In Study 1, patients with colorectal cancer were given irinotecan / 5-FU / leucovorin (bolus-IFL) with or without AVASTIN ."
<p>2894,Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN .
<p>2895,"The concentrations of SN38 , the active metabolite of irinotecan , were on average 33</p> higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone."
<p>2896,"The concentrations of SN38 , the active metabolite of irinotecan , were on average 33</p> higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone."
<p>2897,"The concentrations of SN38 , the active metabolite of irinotecan , were on average 33</p> higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone."
<p>2898,"Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain."
<p>2899,"Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain."
<p>2900,"Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain."
<p>2901,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2902,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2903,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2904,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2905,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2906,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2907,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2908,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations."
<p>2909,"Furthermore, rifampin , phenytoin , phenobarbital , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations."
<p>2910,"Furthermore, rifampin , phenytoin , phenobarbital , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations."
<p>2911,"Furthermore, rifampin , phenytoin , phenobarbital , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations."
<p>2912,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil ."
<p>2913,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil ."
<p>2914,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil ."
<p>2915,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil ."
<p>2916,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil ."
<p>2917,"Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration."
<p>2918,Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
<p>2919,When Bezalip or Bezalip_retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip_retard may enhance the action of anticoagulants_of_the_coumarin_type .
<p>2920,When Bezalip or Bezalip_retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip_retard may enhance the action of anticoagulants_of_the_coumarin_type .
<p>2921,When Bezalip or Bezalip_retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip_retard may enhance the action of anticoagulants_of_the_coumarin_type .
<p>2922,When Bezalip or Bezalip_retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip_retard may enhance the action of anticoagulants_of_the_coumarin_type .
<p>2923,"For this reason, the dose of the anticoagulant should be reduced by # - 50</p> at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters"
<p>2924,"For this reason, the dose of the anticoagulant should be reduced by # - 50</p> at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters"
<p>2925,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip_retard .
<p>2926,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip_retard .
<p>2927,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip_retard .
<p>2928,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip_retard .
<p>2929,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip_retard .
<p>2930,"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate ."
<p>2931,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2932,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2933,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2934,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2935,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2936,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2937,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2938,"- When Bezalip or Bezalip_retard is used concurrently with anion-exchange_resins (e,g, Cholestyramine ), an interval of at least # hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip_retard is impaired"
<p>2939,- Perhexiline_hydrogen_maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip_retard .
<p>2940,- Perhexiline_hydrogen_maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip_retard .
<p>2941,- Perhexiline_hydrogen_maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip_retard .
<p>2942,- Perhexiline_hydrogen_maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip_retard .
<p>2943,- Perhexiline_hydrogen_maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip_retard .
<p>2944,"In vitro studies have shown CASODEX can displace coumarin_anticoagulant s, such as warfarin , from their protein-binding sites."
<p>2945,"In vitro studies have shown CASODEX can displace coumarin_anticoagulant s, such as warfarin , from their protein-binding sites."
<p>2946,"In vitro studies have shown CASODEX can displace coumarin_anticoagulant s, such as warfarin , from their protein-binding sites."
<p>2947,"It is recommended that if CASODEX is started in patients already receiving coumarin_anticoagulants , prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary."
<p>2948,"It is recommended that if CASODEX is started in patients already receiving coumarin_anticoagulants , prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary."
<p>2949,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2950,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2951,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2952,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2953,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2954,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2955,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2956,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2957,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2958,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2959,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2960,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2961,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2962,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2963,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2964,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2965,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2966,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2967,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2968,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2969,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2970,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2971,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2972,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2973,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2974,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2975,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2976,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2977,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2978,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2979,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2980,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2981,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2982,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2983,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2984,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2985,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2986,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2987,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2988,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2989,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2990,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2991,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2992,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2993,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e,g,, certain narcotic_analgesics such as meperidine , the phenothiazines and other antipsychotics , tricyclic_antidepressants , certain antiarrhythmics such as the quinidine salts, and antihistamines ."
<p>2994,ZEBETA should not be combined with other beta-blocking_agents .
<p>2995,"Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine , should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity."
<p>2996,"Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine , should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity."
<p>2997,"Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine , should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity."
<p>2998,"In patients receiving concurrent therapy with clonidine , if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine ."
<p>2999,"In patients receiving concurrent therapy with clonidine , if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine ."
